Alcon Inc 6-K, filed Aug 10, 2026
Alcon Inc (ALC)
6-K
2026-08-10
For: 2026-06-30
View Original
Added on
August 10, 2026
About this 6-K
Alcon Inc filed this 6-K on August 10, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM 6-K
_________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
August 10, 2026
Commission File Number: 001-31269
_________________
(Registrant Name)
(Address of principal executive office)
_________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20‑F or Form 40-F: Form 20-F ☒ Form 40-F ☐
EXHIBIT INDEX
| Exhibit Number | Description | |||||||
| 99.1 | ||||||||
| 99.2 | ||||||||
| 101 | Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes included in this Form 6-K | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | |||||||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ALCON INC. | ||||||||||||||
| Date: | August 10, 2026 | By: | /s/ David J. Endicott | |||||||||||
| Name: David J. Endicott | ||||||||||||||
| Title: Authorized Representative | ||||||||||||||
| Date: | August 10, 2026 | By: | /s/ Timothy C. Stonesifer | |||||||||||
| Name: Timothy C. Stonesifer | ||||||||||||||
| Title: Authorized Representative | ||||||||||||||
3
New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth
•Second-quarter 2026 sales of $2.8 billion, up 8% on a reported basis, or up 7% constant currency1 (cc), versus second-quarter 2025
•Returned $538 million to shareholders through dividends and share repurchases on a year-to-date basis
•Updated full-year guidance - raised core operating margin and core diluted EPS growth
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, August 10, 2026 - Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2026. For the second quarter of 2026, sales were $2.8 billion, up 8% on a reported basis and up 7% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.00 and core diluted earnings per share2 of $0.84 in the second quarter of 2026.
"Our team delivered strong second-quarter results and executed well across the business," said David J. Endicott, Alcon's Chief Executive Officer. "UNITY, PanOptix Pro, TRYPTYR and other recent launches are driving growth and reinforcing the strength of our innovation engine. Across the portfolio, our innovative products continue to gain traction and expand our market positions, including contact lenses where we are continuing to gain share. With a robust pipeline and several important launches ahead, we are well positioned to deliver sustainable long-term growth and further strengthen our leadership in eye care."
Second-quarter and first-half 2026 key figures | Three months ended June 30 | Six months ended June 30 | ||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Net sales ($ millions) | 2,782 | 2,577 | 5,467 | 5,028 | ||||||||||||||||||||||
| Operating margin (%) | 0.4 | 9.6 | 5.5 | 14.2 | ||||||||||||||||||||||
| Diluted earnings per share ($) | 0.00 | 0.35 | 0.39 | 1.06 | ||||||||||||||||||||||
Core results (non-IFRS measure)2 | ||||||||||||||||||||||||||
| Core operating margin (%) | 20.6 | 19.1 | 20.9 | 19.9 | ||||||||||||||||||||||
| Core diluted earnings per share ($) | 0.84 | 0.76 | 1.69 | 1.50 | ||||||||||||||||||||||
| Cash flows ($ millions) | ||||||||||||||||||||||||||
| Net cash flows from operating activities | 928 | 889 | ||||||||||||||||||||||||
Free cash flow (non-IFRS measure)3 | 693 | 681 | ||||||||||||||||||||||||
1.Constant currency (cc) is a non-IFRS measure. An explanation of non-IFRS measures can be found in the 'Non-IFRS measures as defined by the Company' section.
2.Core results, such as core gross margin, core operating income, core operating margin and core diluted EPS, are non-IFRS measures. An explanation of non-IFRS measures can be found in the 'Non-IFRS measures as defined by the Company' section.
3.Free cash flow is a non-IFRS measure. An explanation of non-IFRS measures can be found in the 'Non-IFRS measures as defined by the Company' section.
1
Second-quarter and first-half 2026 results
Reported net sales for the second quarter of 2026 were $2.8 billion, up 8% versus the second quarter of 2025. Excluding favorable currency impacts of 1%, sales were up 7% on a constant currency basis. Reported net sales for the first half of 2026 were $5.5 billion, up 9% versus the first half of 2025. Excluding favorable currency impacts of 2%, sales were up 7% on a constant currency basis.
The following table highlights net sales by segment for the second quarter and first half of 2026:
| Three months ended June 30 | Change % | Six months ended June 30 | Change % | |||||||||||||||||||||||||||||||||||||||||||||||
| ($ millions unless indicated otherwise) | 2026 | 2025 | $ | cc1 (non-IFRS measure) | 2026 | 2025 | $ | cc1 (non-IFRS measure) | ||||||||||||||||||||||||||||||||||||||||||
| Surgical | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Implantables | 466 | 456 | 2 | 1 | 904 | 876 | 3 | 1 | ||||||||||||||||||||||||||||||||||||||||||
| Consumables | 825 | 777 | 6 | 5 | 1,594 | 1,489 | 7 | 5 | ||||||||||||||||||||||||||||||||||||||||||
| Equipment/other | 279 | 222 | 26 | 25 | 532 | 421 | 26 | 24 | ||||||||||||||||||||||||||||||||||||||||||
| Total Surgical | 1,570 | 1,455 | 8 | 7 | 3,030 | 2,786 | 9 | 7 | ||||||||||||||||||||||||||||||||||||||||||
| Vision Care | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Contact lenses | 726 | 692 | 5 | 5 | 1,464 | 1,380 | 6 | 4 | ||||||||||||||||||||||||||||||||||||||||||
| Ocular health | 486 | 430 | 13 | 12 | 973 | 862 | 13 | 11 | ||||||||||||||||||||||||||||||||||||||||||
| Total Vision Care | 1,212 | 1,122 | 8 | 7 | 2,437 | 2,242 | 9 | 7 | ||||||||||||||||||||||||||||||||||||||||||
| Net sales | 2,782 | 2,577 | 8 | 7 | 5,467 | 5,028 | 9 | 7 | ||||||||||||||||||||||||||||||||||||||||||
Net sales by segment
Second quarter
Surgical
Surgical net sales were $1.6 billion, an increase of 8% on a reported basis and 7% on a constant currency basis versus the second quarter of 2025.
•Implantables net sales were $466 million, an increase of 2%. Excluding favorable currency impacts of 1%, Implantables net sales increased 1% constant currency. This growth was driven by an increase in IOLs of 2% constant currency, primarily driven by the strong performance of PanOptix Pro and reflecting competitive pressures, partially offset by lower sales in surgical glaucoma.
•Consumables net sales were $825 million, an increase of 6%. Excluding favorable currency impacts of 1%, Consumables net sales increased 5% constant currency. Growth was driven by procedural growth and price increases with continued softness in the cataract market.
•Equipment/other net sales were $279 million, an increase of 26%. Excluding favorable currency impacts of 1%, Equipment/other net sales increased 25% constant currency. This growth was led by recent equipment launches, including the Unity platform.
Vision Care
Vision Care net sales were $1.2 billion, an increase of 8% on a reported basis and 7% on a constant currency basis versus the second quarter of 2025.
•Contact lenses net sales were $726 million, an increase of 5% on a reported and constant currency basis. This growth reflects product innovation and price increases, partially offset by declines in legacy products.
2
•Ocular health net sales were $486 million, an increase of 13%. Excluding favorable currency impacts of 1%, Ocular health net sales increased 12% constant currency. Growth was led by our portfolio of dry eye products, including Tryptyr and Systane.
First half
Surgical
Surgical net sales were $3.0 billion, an increase of 9% on a reported basis and 7% on a constant currency basis versus the first half of 2025.
•Implantables net sales were $904 million, an increase of 3%. Excluding favorable currency impacts of 2%, Implantables net sales increased 1% constant currency. This growth was driven by an increase in IOLs of 2% constant currency, primarily driven by the strong performance of PanOptix Pro and reflecting competitive pressures, partially offset by lower sales in surgical glaucoma.
•Consumables net sales were $1.6 billion, an increase of 7%. Excluding favorable currency impacts of 2%, Consumables net sales increased 5% constant currency. Growth was driven by procedural growth and price increases with continued softness in the cataract market.
•Equipment/other net sales were $532 million, an increase of 26%. Excluding favorable currency impacts of 2%, Equipment/other net sales increased 24% constant currency. This growth was led by recent equipment launches, including the Unity platform.
Vision Care
Vision Care net sales were $2.4 billion, an increase of 9% on a reported basis and 7% on a constant currency basis versus the first half of 2025.
•Contact lenses net sales were $1.5 billion, an increase of 6%. Excluding favorable currency impacts of 2%, Contact lenses net sales increased 4% constant currency. This growth reflects product innovation and price increases, partially offset by declines in legacy products.
•Ocular health net sales were $973 million, an increase of 13%. Excluding favorable currency impacts of 2%, Ocular health net sales increased 11% constant currency. Growth was led by our portfolio of dry eye products, including Tryptyr and Systane.
Operating income
Second quarter
Operating income in the current year period was offset by the decision to discontinue the IOL programs acquired from PowerVision, Inc. in March 2019 ("PowerVision programs") following the analysis of the latest clinical study data. The PowerVision programs did not produce acceptable patient outcomes based principally on persistent unpredictable post-surgical visual outcomes reported in a subset of the patients that could not be resolved despite multiple development efforts. As part of the decision to discontinue the PowerVision programs, the Company recorded a pre-tax, non-cash net charge of $402 million (post-tax of $287 million) in the current year period. The net charge has no impact on the Company's cash position and does not change the Company’s previously communicated long-range financial objectives.
3
Operating income was $11 million (-96%, -97% cc), compared to $247 million in the prior year period. Operating margin decreased 9.2 percentage points on a reported basis and 9.3 percentage points on a constant currency basis. The current year period included a pre-tax, non-cash net charge of $402 million related to the discontinuation of the PowerVision programs discussed above, costs associated with efficiency measures and sales and marketing behind new product launches, partially offset by lower amortization, manufacturing efficiencies and $15 million of other revenue from a licensee. The prior year period included charges related to the discontinued commercialization of a Vision Care product and higher inventory-related costs.
Adjustments to arrive at core operating income in the current year period were $563 million, mainly due to a pre-tax, non-cash net charge of $402 million related to the discontinuation of the PowerVision programs, $128 million of amortization and $33 million of costs associated with efficiency measures. Adjustments to arrive at core operating income in the prior year period were $244 million, mainly due to $173 million of amortization and $44 million of product discontinuation charges.
Core operating income was $574 million (+17%, +16% cc), compared to $491 million in the prior year period. Core operating margin increased 1.5 percentage points on a reported basis and 1.6 percentage points on a constant currency basis. The current year period included manufacturing efficiencies and $15 million of other revenue from a licensee, partially offset by sales and marketing behind new product launches. The prior year period included higher inventory-related costs.
First half
Operating income was $303 million (-58%, -61% cc), compared to $715 million in the prior year period. Operating margin decreased 8.7 percentage points on a reported basis and 9.1 percentage points on a constant currency basis. The current year period included a pre-tax, non-cash net charge of $402 million related to the discontinuation of the PowerVision programs, costs associated with efficiency measures, sales and marketing behind new product launches, impairment charges related to a currently marketed product intangible asset and incremental tariffs, partially offset by lower amortization and manufacturing efficiencies. The prior year period included gains on fair value remeasurements of investments in associated companies, partially offset by charges related to the discontinued commercialization of a Vision Care product.
Adjustments to arrive at core operating income in the current year period were $840 million, mainly due to a pre-tax, non-cash net charge of $402 million related to the discontinuation of the PowerVision programs, $257 million of amortization, $121 million of costs associated with efficiency measures, $38 million of impairment charges related to a currently marketed product intangible asset and $21 million of acquisition and integration related items. Adjustments to arrive at core operating income in the prior year period were $287 million, mainly due to $345 million of amortization, $44 million of product discontinuation charges and $23 million of acquisition and integration related items, partially offset by gains of $142 million on fair value remeasurements of investments in associated companies.
Core operating income was $1.1 billion (+14%, +11% cc), compared to $1.0 billion in the prior year period. Core operating margin increased 1.0 percentage points on a reported basis and 0.9 percentage points on a constant currency basis. The current year period included manufacturing efficiencies, partially offset by sales and marketing behind new product launches and incremental tariffs.
Taxes
Second quarter
There was a reported tax benefit of $46 million in the current year period, compared to a tax expense of $23 million in the prior year period. The current year tax benefit was primarily driven by the reversal of deferred tax liabilities of $115 million related to the discontinuation of the PowerVision programs. The prior year period included a more favorable mix of pre-tax income/(loss) across geographical tax jurisdictions and a net benefit from discrete tax items.
4
Core tax expense was $107 million, compared to $63 million in the prior year period, and the average core tax rate was 20.7%, compared to 14.2% in the prior year period. The increase in the average core tax rate was primarily driven by a more favorable mix of pre-tax income/(loss) across geographical tax jurisdictions and a net benefit from discrete tax items in the prior year period.
First half
Reported tax expense was $5 million, compared to $87 million in the prior year period, and the average reported tax rate was 2.6%, compared to 14.2% in the prior year period. The average reported tax rate in the current year period was impacted by a $115 million tax benefit from the reversal of deferred tax liabilities related to the discontinuation of the PowerVision programs. The average reported rate in the prior year period included a non-taxable gain on the fair value remeasurement of an investment in an associated company and net benefits from discrete tax items.
Core tax expense was $209 million, compared to $160 million in the prior year period, and the average core tax rate was 20.2%, compared to 17.7% in the prior year period. The prior year period included net benefits from discrete tax items.
Diluted earnings per share
Second quarter
Diluted earnings per share of $0.00, compared to $0.35 in the prior year period, primarily as a result of a post-tax, non-cash net charge of approximately $287 million related to the discontinuation of the PowerVision programs. Core diluted earnings per share of $0.84 increased 11%, or 9% on a constant currency basis, versus the prior year period.
First half
Diluted earnings per share of $0.39 decreased 63%, or 68% on a constant currency basis, versus the prior year period, primarily due to a post-tax, non-cash net charge of approximately $287 million related to the discontinuation of the PowerVision programs and costs associated with efficiency measures. The prior year period included gains of $142 million on fair value remeasurements of investments in associated companies. Core diluted earnings per share of $1.69 increased 13%, or 10% on a constant currency basis, versus the prior year period.
Cash flow highlights
Net cash flows from operating activities amounted to $928 million for the first six months of 2026, compared to $889 million in the prior year period. Free cash flow was $693 million for the six months of 2026, compared to $681 million in the prior year period.
5
Capital allocation
The Company returned $469 million to shareholders in the second quarter, which included $174 million of dividends, and $295 million of share repurchases. As of June 30, 2026, the Company had approximately $1.2 billion remaining of its previously announced $1.5 billion authorization.
On a year-to-date basis through the second quarter, the Company has returned $538 million to shareholders through dividends and share repurchases.
Alcon continues to expect to fund the program through cash generated from operations. The program is subject to customary safe harbor conditions and authorization of the Swiss Takeover Board. The timing and total amount of share repurchases and cancellations will depend upon a variety of factors. The program is expected to be completed over a three-year period, but may be suspended or discontinued at any time.
Further information (including official publications in English, German and French) is available at https://investor.alcon.com/stock-information/share-repurchase-history/default.aspx.
6
2026 outlook
The Company updated its 2026 outlook as per the table below.
2026 outlook4 | as of May | as of August | Comments | ||||||||
Net sales growth vs. prior year (cc)1 (non-IFRS measure) | +5% to +7% | +5% to +7% | Maintained | ||||||||
Core operating margin2 change vs. prior year (cc)1 (non-IFRS measure) | +70 to +170 bps | +90 to +190 bps | Increased | ||||||||
Core diluted EPS2 growth vs. prior year (cc)1 (non-IFRS measure) | +10% to +13% | '+12% to +15% | Increased | ||||||||
This outlook assumes the following:
•Aggregated markets grow approximately 3% to 4%
•The Company expects a full-year tariff impact, net of mitigating actions and refunds, of approximately $40 million to $90 million, which is expected to pressure cost of net sales. This estimate assumes that the tariffs currently applicable to Alcon's business remain in effect through year-end, including U.S. import tariff rates of approximately 10% to 12.5%. This also reflects an anticipated refund of approximately $60 million from the U.S. government in the third quarter of 2026. Approximately two-thirds of the refund benefit is expected to be reinvested in the business.
•Exchange rates as of the end of July 2026 prevail through year-end
•As of the end of July the expected currency impact to:
◦Net sales growth is +90 basis points
◦Core operating margin rate is +10 basis points
◦Core diluted EPS growth is +170 basis points
•Non-operating expense5 for FY 2026 is expected to be between $200 and $220 million
•The core effective tax rate6 for FY 2026 is expected to be approximately 20%
•Capital expenditures are expected to be mid-single digits as a percentage of sales
•Approximately 488 million weighted-averaged diluted shares7
4.The forward-looking guidance included in this press release cannot be reconciled to the comparable IFRS measures without unreasonable effort, because we are not able to predict with reasonable certainty the ultimate amount or nature of exceptional items in the fiscal year. Refer to the section 'Non-IFRS measures as defined by the Company' for more information.
5.Non-operating income & expense includes interest expense, other financial income & expense and share of loss from associated companies.
6.Core effective tax rate, a non-IFRS measure, is the applicable annual tax rate on core taxable income. For additional information, see the explanation regarding reconciliation of forward-looking guidance in the 'Non-IFRS measures as defined by the Company' section.
7.The estimated share count used in the Company's guidance excludes any potential benefit from future share repurchase activity.
7
Other Notable Accomplishments
•Earned MedTech Breakthrough’s 2026 Best Practice Management Solution award for Alcon’s Adi Digital Ecosystem, recognizing its role in modernizing cataract surgery workflows by connecting inventory management, online ordering and clinic-to-OR coordination.
•Showcased Alcon’s thought leadership at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., with more than 60 scientific presentations and peer-to-peer educational symposia highlighting the company’s clinical and technology innovation.
•Advanced ophthalmic innovation through Alcon’s partnership with ARVO, a global association for eye and vision researchers. The 2026 Live Eye Pitch Event spotlights emerging eye and vision research and connects the winner to Alcon Seed Fund diligence for potential investment.
•Celebrated more than 30 years of Alcon WaveLight innovation, reinforcing three decades of precision engineering, bold innovation and commitment to advancing quality eye care.
•Announced a non-exclusive collaboration with RxSight to jointly develop adjustable presbyopia-correcting intraocular lenses, combining Alcon’s PCIOL optical designs with RxSight’s post-operative light-adjustable technology to help surgeons fine-tune visual outcomes after cataract surgery.
•Engaged nearly 5,200 employees in Alcon in Action, the company’s annual global volunteer initiative, supporting communities across 32 countries through health, nutrition, housing and environmental initiatives.
•Earned global recognition as an employer of choice, including honors from Forbes, Ethisphere and the Human Rights Campaign.
•Expanded Alcon Cares' impact through $23.4 million of product donations year-to-date, supporting medical missions, patient assistance and disaster relief programs, while placing donated equipment across 12 charitable care initiatives globally.
8
Webcast and Conference Call Instructions
The Company will host a conference call on August 11 2026 at 8:00 a.m. Eastern Time / 2:00 p.m. Central European Time to discuss its second-quarter 2026 earnings results. The webcast can be accessed online through Alcon's Investor Relations website, i.e. investor.alcon.com. Listeners should log on approximately 10 minutes in advance. A replay will be available online within 24 hours after the event. To listen the Company's conference call, click on the link:
https://investor.alcon.com/news-and-events/events-and-presentations/event-details/2026/Alcons-Second-Quarter-2026-Earnings-Call-2026-fRS9bIWOaB/default.aspx
The Company's second-quarter 2026 press release, interim financial report and supplemental presentation materials can be found online through Alcon's Investor Relations website, or by clicking on the link:
https://investor.alcon.com/news-and-events/events-and-presentations/event-details/2026/Alcons-Second-Quarter-2026-Earnings-Call-2026-fRS9bIWOaB/default.aspx
Cautionary Note Regarding Forward-Looking Statements
This press release contains, and our officers and representatives may from time to time make, certain “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “target,” “assume,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our 2026 outlook, liquidity, revenue, revenue growth, gross margin, operating margin, core operating margin, core operating margin growth, effective tax rate, foreign currency exchange movements, tariff impact, nonoperating expenses, earnings per share, earnings per share growth, operating cash flow, free cash flow, our plans and decisions relating to various capital expenditures, capital allocation priorities and other discretionary items such as our market growth assumptions, our social impact and sustainability plans, targets, goals and expectations, and generally, our expectations concerning our future performance.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict such as: cybersecurity breaches and technology failures that could disrupt operations; our ability to effectively manage the risks associated with transformational information technology changes such as the ethical use of artificial intelligence and disruptive technologies and the migration to cloud-based platforms; compliance with data privacy, identity protection and information security laws, particularly with the increased use of artificial intelligence; the impact of a disruption in our global supply chain, including the effect of tariffs, or important facilities, particularly when we single-source or rely on limited sources of supply; our reliance on outsourcing key business functions; the increasingly challenging economic, political and legal environment in China; global and regional economic, financial, monetary, legal, tax, political and social change; our ability to comply with anti-corruption, anti-bribery, export control, trade sanction, or similar laws; our ability to attract and retain qualified personnel; our ability to manage the risks associated with operating as a third party contract manufacturer; our success in completing strategic acquisitions, including equity investments in early-stage companies, on favorable terms or at all, and in integrating acquired businesses; the success of our research and development efforts, including our ability to innovate to compete effectively; our ability to manage the rapid evolution and adoption of artificial intelligence; terrorism, war and similar events; our ability to forecast sales demand and manage our inventory levels and the changing buying patterns of our
9
customers; pricing pressure from changes in third party payor coverage and reimbursement methodologies; our ability to comply with all laws to which we may be subject; the ability to obtain regulatory clearance and approval of our products as well as compliance with any post-approval obligations, including quality control of our manufacturing; the effect of product recalls or voluntary market withdrawals; our ability to manage social impact and sustainability matters; our ability to properly educate and train healthcare providers on our products; our ability to protect our intellectual property; the accuracy of our accounting estimates and assumptions, including pension and other post-employment benefit plan obligations and the carrying value of intangible assets, and the adequacy of our financial reporting, accounting practices and internal controls; our ability to service our debt obligations; the need for additional financing through the issuance of debt or equity; the effects of litigation, including product liability lawsuits and governmental investigations; legislative, tax and regulatory reform; the impact of being listed on two stock exchanges; the ability to declare and pay dividends; the different rights afforded to our shareholders as a Swiss corporation compared to a US corporation; the effect of maintaining or losing our foreign private issuer status under US securities laws; and the ability to enforce US judgments against Swiss corporations.
Additional factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise. We also undertake no obligation to update the 2026 outlook as circumstances evolve.
Intellectual Property
This report may contain references to our proprietary intellectual property. All product names appearing in italics or ALL CAPS are trademarks owned by or licensed to Alcon Inc. Product names identified by a "®" or a "™" are trademarks that are not owned by or licensed to Alcon or its subsidiaries and are the property of their respective owners.
Non-IFRS measures as defined by the Company
Alcon uses certain non-IFRS metrics when measuring performance, including when measuring current period results against prior periods, including core results, percentage changes measured in constant currency, EBITDA, free cash flow and net (debt)/liquidity.
Because of their non-standardized definitions, the non-IFRS measures (unlike IFRS measures) may not be comparable to the calculation of similar measures of other companies. These supplemental non-IFRS measures are presented solely to permit investors to more fully understand how Alcon management assesses underlying performance. These supplemental non-IFRS measures are not, and should not be viewed as, a substitute for IFRS measures.
10
Core results
Alcon core results, including core operating income and core net income, exclude all amortization and impairment charges of intangible assets, excluding software, all fair value adjustments to contingent considerations from acquisitions, other than changes due to the time value of money, product discontinuation charges, net gains and losses on fund investments and equity securities valued at fair value through profit and loss ("FVPL"), fair value adjustments of financial assets in the form of options to acquire a company carried at FVPL, fair value remeasurements of investments in associated companies and certain acquisition related items. The following items that exceed a threshold of $10 million, are not operating expenses necessary to the operation of the business and have costs that will vary over periods and are also excluded from core results: integration and divestment related income and expenses, divestment gains and losses, restructuring charges/releases and related items, legal related items, gains/losses on early extinguishment of debt or debt modifications, past service costs for post-employment benefit plans, impairments of property, plant and equipment and software, as well as income and expense items that management deems exceptional and that are or are expected to accumulate within the year to be over a $10 million threshold.
Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on other items, although this is not always the case for certain items such as legal settlements in certain jurisdictions.
Alcon believes that investor understanding of its performance is enhanced by disclosing core measures of performance because, since they exclude items that can vary significantly from period to period, the core measures enable a helpful comparison of business performance across periods. For this same reason, Alcon uses these core measures in addition to IFRS and other measures as important factors in assessing its performance.
A limitation of the core measures is that they provide a view of Alcon operations without including all events during a period, such as the effects of an acquisition, divestment, or amortization/impairments of purchased intangible assets and restructurings.
Constant currency
Changes in the relative values of non-US currencies to the US dollar can affect Alcon's financial results and financial position. To provide additional information that may be useful to investors, including changes in sales volume, we present information about changes in our net sales and various values relating to operating and net income that are adjusted for such foreign currency effects.
Constant currency calculations have the goal of eliminating two exchange rate effects so that an estimate can be made of underlying changes in the Consolidated Income Statement excluding:
•the impact of translating the income statements of consolidated entities from their non-US dollar functional currencies to the US dollar; and
•the impact of exchange rate movements on the major transactions of consolidated entities performed in currencies other than their functional currency.
Alcon calculates constant currency measures by translating the current year's foreign currency values for sales and other income statement items into US dollars, using the average exchange rates from the historical comparative period and comparing them to the values from the historical comparative period in US dollars.
11
EBITDA
Alcon defines earnings before interest, tax, depreciation and amortization ("EBITDA") as net income excluding income taxes, depreciation of property, plant and equipment (including any related impairment charges), depreciation of right-of-use assets, amortization of intangible assets (including any related impairment charges), interest expense and other financial income and expense. Alcon management primarily uses EBITDA together with net (debt)/liquidity to monitor leverage associated with financial debts.
Free cash flow
Alcon defines free cash flow as net cash flows from operating activities less cash flow associated with the purchase or sale of property, plant and equipment. Free cash flow is presented as additional information because Alcon management believes it is a useful supplemental indicator of Alcon's ability to operate without reliance on additional borrowing or use of existing cash. Free cash flow is not intended to be a substitute measure for net cash flows from operating activities as determined under IFRS.
Net (debt)/liquidity
Alcon defines net (debt)/liquidity as current and non-current financial debt less cash and cash equivalents, current investments, including time deposits, and derivative financial instruments. Net (debt)/liquidity is presented as additional information because management believes it is a useful supplemental indicator of Alcon's ability to pay dividends, to meet financial commitments and to invest in new strategic opportunities, including strengthening its balance sheet.
Growth rate and margin calculations
For ease of understanding, Alcon uses a sign convention for its growth rates such that a reduction in operating expenses or losses compared to the prior year is shown as a positive growth.
Gross margins, core gross margins, operating income margins and core operating income margins are calculated based upon net sales unless otherwise noted.
Reconciliation of guidance for forward-looking non-IFRS measures
The forward-looking guidance included in this press release cannot be reconciled to the comparable IFRS measures without unreasonable efforts, because we are not able to predict with reasonable certainty the ultimate amount or nature of exceptional items in the fiscal year. These items are uncertain, depend on many factors and could have a material impact on our IFRS results for the guidance period.
12
Financial tables
Net sales by region
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ($ millions unless indicated otherwise) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| United States | 1,241 | 45 | % | 1,160 | 45 | % | 2,469 | 45 | % | 2,297 | 46 | % | ||||||||||||||||||||||||||||||||||||||||||||
| International | 1,541 | 55 | % | 1,417 | 55 | % | 2,998 | 55 | % | 2,731 | 54 | % | ||||||||||||||||||||||||||||||||||||||||||||
| Net sales | 2,782 | 100 | % | 2,577 | 100 | % | 5,467 | 100 | % | 5,028 | 100 | % | ||||||||||||||||||||||||||||||||||||||||||||
Consolidated Income Statement (unaudited)
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||||||||||||||||||||||||||||
| ($ millions except earnings per share) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||||||||||||||||||||
| Net sales | 2,782 | 2,577 | 5,467 | 5,028 | ||||||||||||||||||||||||||||||||||||||||
| Other revenues | 41 | 19 | 62 | 41 | ||||||||||||||||||||||||||||||||||||||||
| Net sales and other revenues | 2,823 | 2,596 | 5,529 | 5,069 | ||||||||||||||||||||||||||||||||||||||||
| Cost of net sales | (1,130) | (1,196) | (2,293) | (2,267) | ||||||||||||||||||||||||||||||||||||||||
| Cost of other revenues | (18) | (12) | (36) | (31) | ||||||||||||||||||||||||||||||||||||||||
| Gross profit | 1,675 | 1,388 | 3,200 | 2,771 | ||||||||||||||||||||||||||||||||||||||||
| Selling, general & administration | (964) | (870) | (1,846) | (1,683) | ||||||||||||||||||||||||||||||||||||||||
| Research & development | (663) | (245) | (908) | (467) | ||||||||||||||||||||||||||||||||||||||||
| Other income | 6 | 5 | 17 | 154 | ||||||||||||||||||||||||||||||||||||||||
| Other expense | (43) | (31) | (160) | (60) | ||||||||||||||||||||||||||||||||||||||||
| Operating income | 11 | 247 | 303 | 715 | ||||||||||||||||||||||||||||||||||||||||
| Interest expense | (53) | (51) | (105) | (100) | ||||||||||||||||||||||||||||||||||||||||
| Other financial income & expense | — | 4 | 2 | 13 | ||||||||||||||||||||||||||||||||||||||||
| Share of loss from associated companies | (4) | (1) | (6) | (15) | ||||||||||||||||||||||||||||||||||||||||
| (Loss)/income before taxes | (46) | 199 | 194 | 613 | ||||||||||||||||||||||||||||||||||||||||
| Taxes | 46 | (23) | (5) | (87) | ||||||||||||||||||||||||||||||||||||||||
| Net income | — | 176 | 189 | 526 | ||||||||||||||||||||||||||||||||||||||||
| Net income attributable to: | ||||||||||||||||||||||||||||||||||||||||||||
| Shareholders of Alcon Inc. | — | 176 | 189 | 526 | ||||||||||||||||||||||||||||||||||||||||
| Non-controlling interests | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
Earnings per share ($)(1) | ||||||||||||||||||||||||||||||||||||||||||||
| Basic | 0.00 | 0.36 | 0.39 | 1.06 | ||||||||||||||||||||||||||||||||||||||||
| Diluted | 0.00 | 0.35 | 0.39 | 1.06 | ||||||||||||||||||||||||||||||||||||||||
Weighted average number of shares outstanding (millions) | ||||||||||||||||||||||||||||||||||||||||||||
| Basic | 486.7 | 495.2 | 486.9 | 495.2 | ||||||||||||||||||||||||||||||||||||||||
| Diluted | 488.7 | 497.9 | 489.4 | 497.9 | ||||||||||||||||||||||||||||||||||||||||
(1) Earnings per share is calculated on the amount of net income attributable to shareholders of Alcon Inc.
13
Segment contribution
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||||||||||||||||
| Change % | Change % | |||||||||||||||||||||||||||||||
| ($ millions unless indicated otherwise) | 2026 | 2025 | $ | cc(1) (non-IFRS measure) | 2026 | 2025 | $ | cc(1) (non-IFRS measure) | ||||||||||||||||||||||||
| Surgical segment contribution | 392 | 378 | 4 | 2 | 759 | 714 | 6 | 3 | ||||||||||||||||||||||||
| As % of net sales | 25.0 | 26.0 | 25.0 | 25.6 | ||||||||||||||||||||||||||||
| Vision Care segment contribution | 283 | 208 | 36 | 37 | 577 | 489 | 18 | 17 | ||||||||||||||||||||||||
| As % of net sales | 23.3 | 18.5 | 23.7 | 21.8 | ||||||||||||||||||||||||||||
| Not allocated to segments | (664) | (339) | (96) | (96) | (1,033) | (488) | (112) | (111) | ||||||||||||||||||||||||
| Operating income | 11 | 247 | (96) | (97) | 303 | 715 | (58) | (61) | ||||||||||||||||||||||||
Core adjustments (non-IFRS measure)(1) | 563 | 244 | 840 | 287 | ||||||||||||||||||||||||||||
Core operating income (non-IFRS measure)(1) | 574 | 491 | 17 | 16 | 1,143 | 1,002 | 14 | 11 | ||||||||||||||||||||||||
(1)Core results and constant currency are non-IFRS measures. Refer to the 'Non-IFRS measures as defined by the Company' section for additional information and to the 'Reconciliation of IFRS results to core results (non-IFRS measure)' section for reconciliation tables.
Operating income
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||||||||||||||||
| Change % | Change % | |||||||||||||||||||||||||||||||
| ($ millions unless indicated otherwise) | 2026 | 2025 | $ | cc(1) (non-IFRS measure) | 2026 | 2025 | $ | cc(1) (non-IFRS measure) | ||||||||||||||||||||||||
| Cost of net sales | (1,130) | (1,196) | 6 | 6 | (2,293) | (2,267) | (1) | — | ||||||||||||||||||||||||
| Gross profit | 1,675 | 1,388 | 21 | 20 | 3,200 | 2,771 | 15 | 13 | ||||||||||||||||||||||||
| Gross margin (%) | 60.2 | 53.9 | 58.5 | 55.1 | ||||||||||||||||||||||||||||
| Selling, general & administration | (964) | (870) | (11) | (10) | (1,846) | (1,683) | (10) | (8) | ||||||||||||||||||||||||
| Research & development | (663) | (245) | (171) | (170) | (908) | (467) | (94) | (93) | ||||||||||||||||||||||||
| Other income | 6 | 5 | 20 | 8 | 17 | 154 | (89) | (89) | ||||||||||||||||||||||||
| Other expense | (43) | (31) | (39) | (33) | (160) | (60) | (167) | (161) | ||||||||||||||||||||||||
| Operating income | 11 | 247 | (96) | (97) | 303 | 715 | (58) | (61) | ||||||||||||||||||||||||
| Operating margin (%) | 0.4 | 9.6 | 5.5 | 14.2 | ||||||||||||||||||||||||||||
Core results (non-IFRS measure)(1) | ||||||||||||||||||||||||||||||||
| Core gross profit | 1,799 | 1,604 | 12 | 11 | 3,490 | 3,154 | 11 | 8 | ||||||||||||||||||||||||
| Core gross margin (%) | 64.7 | 62.2 | 63.8 | 62.7 | ||||||||||||||||||||||||||||
| Core operating income | 574 | 491 | 17 | 16 | 1,143 | 1,002 | 14 | 11 | ||||||||||||||||||||||||
| Core operating margin (%) | 20.6 | 19.1 | 20.9 | 19.9 | ||||||||||||||||||||||||||||
(1) Core results and constant currency are non-IFRS measures. Refer to the 'Non-IFRS measures as defined by the Company' section for additional information and to the 'Reconciliation of IFRS results to core results (non-IFRS measure)' section for reconciliation tables.
14
Non-operating income & expense
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||||||||||||||||
| Change % | Change % | |||||||||||||||||||||||||||||||
| ($ millions unless indicated otherwise) | 2026 | 2025 | $ | cc(1) (non-IFRS measure) | 2026 | 2025 | $ | cc(1) (non-IFRS measure) | ||||||||||||||||||||||||
| Operating income | 11 | 247 | (96) | (97) | 303 | 715 | (58) | (61) | ||||||||||||||||||||||||
| Interest expense | (53) | (51) | (4) | (4) | (105) | (100) | (5) | (4) | ||||||||||||||||||||||||
| Other financial income & expense | — | 4 | (100) | (108) | 2 | 13 | (85) | (89) | ||||||||||||||||||||||||
| Share of loss from associated companies | (4) | (1) | (300) | (230) | (6) | (15) | 60 | 64 | ||||||||||||||||||||||||
| (Loss)/income before taxes | (46) | 199 | nm | nm | 194 | 613 | (68) | (73) | ||||||||||||||||||||||||
| Taxes | 46 | (23) | nm | nm | (5) | (87) | 94 | 94 | ||||||||||||||||||||||||
| Net income | — | 176 | (100) | (104) | 189 | 526 | (64) | (69) | ||||||||||||||||||||||||
| Net income attributable to: | ||||||||||||||||||||||||||||||||
| Shareholders of Alcon Inc. | — | 176 | (100) | (104) | 189 | 526 | (64) | (69) | ||||||||||||||||||||||||
| Non-controlling interests | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||
Basic earnings per share ($)(2) | 0.00 | 0.36 | (100) | (104) | 0.39 | 1.06 | (63) | (68) | ||||||||||||||||||||||||
Diluted earnings per share ($)(2) | 0.00 | 0.35 | (100) | (104) | 0.39 | 1.06 | (63) | (68) | ||||||||||||||||||||||||
Core results (non-IFRS measure)(1) | ||||||||||||||||||||||||||||||||
| Core taxes | (107) | (63) | (70) | (73) | (209) | (160) | (31) | (28) | ||||||||||||||||||||||||
| Core net income | 410 | 380 | 8 | 7 | 825 | 745 | 11 | 8 | ||||||||||||||||||||||||
| Core net income attributable to: | ||||||||||||||||||||||||||||||||
| Shareholders of Alcon Inc. | 410 | 380 | 8 | 7 | 825 | 745 | 11 | 8 | ||||||||||||||||||||||||
| Non-controlling interests | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||
Core basic earnings per share ($)(2) | 0.84 | 0.77 | 9 | 9 | 1.69 | 1.50 | 13 | 10 | ||||||||||||||||||||||||
Core diluted earnings per share ($)(2) | 0.84 | 0.76 | 11 | 9 | 1.69 | 1.50 | 13 | 10 | ||||||||||||||||||||||||
nm = not meaningful
(1)Core results and constant currency are non-IFRS measures. Refer to the 'Non-IFRS measures as defined by the Company' section for additional information and to the 'Reconciliation of IFRS results to core results (non-IFRS measure)' section for reconciliation tables.
(2)Earnings per share and core earnings per share are calculated on the amount of net income and core net income, respectively, attributable to shareholders of Alcon Inc.
15
Reconciliation of IFRS results to core results (non-IFRS measure)
Three months ended June 30, 2026
| ($ millions except earnings per share) | IFRS results | Amortization of certain intangible assets(1) | Discontinuation of the PowerVision programs(2) | Efficiency measures(6) | Other items(9) | Core results (non-IFRS measure) | ||||||||||||||||||||||||||||||||
| Gross profit | 1,675 | 124 | — | — | — | 1,799 | ||||||||||||||||||||||||||||||||
| Operating income | 11 | 128 | 402 | 33 | — | 574 | ||||||||||||||||||||||||||||||||
| (Loss)/income before taxes | (46) | 128 | 402 | 33 | — | 517 | ||||||||||||||||||||||||||||||||
Taxes(10) | 46 | (21) | (115) | (6) | (11) | (107) | ||||||||||||||||||||||||||||||||
| Net income | — | 107 | 287 | 27 | (11) | 410 | ||||||||||||||||||||||||||||||||
| Net income attributable to: | ||||||||||||||||||||||||||||||||||||||
| Shareholders of Alcon Inc. | — | 107 | 287 | 27 | (11) | 410 | ||||||||||||||||||||||||||||||||
| Non-controlling interests | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||
Basic earnings per share ($)(11) | 0.00 | 0.84 | ||||||||||||||||||||||||||||||||||||
Diluted earnings per share ($)(11) | 0.00 | 0.84 | ||||||||||||||||||||||||||||||||||||
Basic - weighted average shares outstanding (millions)(11) | 486.7 | 486.7 | ||||||||||||||||||||||||||||||||||||
Diluted - weighted average shares outstanding (millions)(11) | 488.7 | 488.7 | ||||||||||||||||||||||||||||||||||||
Refer to the associated explanatory footnotes at the end of the 'Reconciliation of IFRS results to core results (non-IFRS measure)' tables.
Three months ended June 30, 2025
| ($ millions except earnings per share) | IFRS results | Amortization of certain intangible assets(1) | Acquisition and integration related items(5) | Legal items(7) | Product discontinuation(8) | Other items(9) | Core results (non-IFRS measure) | ||||||||||||||||||||||
| Gross profit | 1,388 | 172 | — | — | 44 | — | 1,604 | ||||||||||||||||||||||
| Operating income | 247 | 173 | 10 | 17 | 44 | — | 491 | ||||||||||||||||||||||
| Income before taxes | 199 | 173 | 10 | 17 | 44 | — | 443 | ||||||||||||||||||||||
Taxes(10) | (23) | (32) | (2) | (4) | (10) | 8 | (63) | ||||||||||||||||||||||
| Net income | 176 | 141 | 8 | 13 | 34 | 8 | 380 | ||||||||||||||||||||||
| Net income attributable to: | |||||||||||||||||||||||||||||
| Shareholders of Alcon Inc. | 176 | 141 | 8 | 13 | 34 | 8 | 380 | ||||||||||||||||||||||
| Non-controlling interests | — | — | — | — | — | — | — | ||||||||||||||||||||||
Basic earnings per share ($)(11) | 0.36 | 0.77 | |||||||||||||||||||||||||||
Diluted earnings per share ($)(11) | 0.35 | 0.76 | |||||||||||||||||||||||||||
Basic - weighted average shares outstanding (millions)(11) | 495.2 | 495.2 | |||||||||||||||||||||||||||
Diluted - weighted average shares outstanding (millions)(11) | 497.9 | 497.9 | |||||||||||||||||||||||||||
Refer to the associated explanatory footnotes at the end of the 'Reconciliation of IFRS results to core results (non-IFRS measure)' tables.
16
Six months ended June 30, 2026
| ($ millions except earnings per share) | IFRS results | Amortization of certain intangible assets(1) | Discontinuation of the PowerVision programs(2) | Impairments(3) | Acquisition and integration related items(5) | Efficiency measures(6) | Other items(9) | Core results (non-IFRS measure) | ||||||||||||||||||||||||||||||
| Gross profit | 3,200 | 251 | — | 38 | 1 | — | — | 3,490 | ||||||||||||||||||||||||||||||
| Operating income | 303 | 257 | 402 | 38 | 21 | 121 | 1 | 1,143 | ||||||||||||||||||||||||||||||
| Income before taxes | 194 | 257 | 402 | 38 | 21 | 121 | 1 | 1,034 | ||||||||||||||||||||||||||||||
Taxes(10) | (5) | (44) | (115) | (6) | (4) | (23) | (12) | (209) | ||||||||||||||||||||||||||||||
| Net income | 189 | 213 | 287 | 32 | 17 | 98 | (11) | 825 | ||||||||||||||||||||||||||||||
| Net income attributable to: | ||||||||||||||||||||||||||||||||||||||
| Shareholders of Alcon Inc. | 189 | 213 | 287 | 32 | 17 | 98 | (11) | 825 | ||||||||||||||||||||||||||||||
| Non-controlling interests | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
Basic earnings per share ($)(11) | 0.39 | 1.69 | ||||||||||||||||||||||||||||||||||||
Diluted earnings per share ($)(11) | 0.39 | 1.69 | ||||||||||||||||||||||||||||||||||||
Basic - weighted average shares outstanding (millions)(11) | 486.9 | 486.9 | ||||||||||||||||||||||||||||||||||||
Diluted - weighted average shares outstanding (millions)(11) | 489.4 | 489.4 | ||||||||||||||||||||||||||||||||||||
Refer to the associated explanatory footnotes at the end of the 'Reconciliation of IFRS results to core results (non-IFRS measure)' tables.
Six months ended June 30, 2025
| ($ millions except earnings per share) | IFRS results | Amortization of certain intangible assets(1) | Gains on investments in associated companies(4) | Acquisition and integration related items(5) | Legal items(7) | Product discontinuation(8) | Other items(9) | Core results (non-IFRS measure) | |||||||||||||||||||||||||||||||||
| Gross profit | 2,771 | 339 | — | — | — | 44 | — | 3,154 | |||||||||||||||||||||||||||||||||
| Operating income | 715 | 345 | (142) | 23 | 17 | 44 | — | 1,002 | |||||||||||||||||||||||||||||||||
| Income before taxes | 613 | 345 | (142) | 23 | 17 | 44 | 5 | 905 | |||||||||||||||||||||||||||||||||
Taxes(10) | (87) | (62) | — | (5) | (4) | (10) | 8 | (160) | |||||||||||||||||||||||||||||||||
| Net income | 526 | 283 | (142) | 18 | 13 | 34 | 13 | 745 | |||||||||||||||||||||||||||||||||
| Net income attributable to: | |||||||||||||||||||||||||||||||||||||||||
| Shareholders of Alcon Inc. | 526 | 283 | (142) | 18 | 13 | 34 | 13 | 745 | |||||||||||||||||||||||||||||||||
| Non-controlling interests | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
Basic earnings per share ($)(11) | 1.06 | 1.50 | |||||||||||||||||||||||||||||||||||||||
Diluted earnings per share ($)(11) | 1.06 | 1.50 | |||||||||||||||||||||||||||||||||||||||
Basic - weighted average shares outstanding (millions)(11) | 495.2 | 495.2 | |||||||||||||||||||||||||||||||||||||||
Diluted - weighted average shares outstanding (millions)(11) | 497.9 | 497.9 | |||||||||||||||||||||||||||||||||||||||
Refer to the associated explanatory footnotes at the end of the 'Reconciliation of IFRS results to core results (non-IFRS measure)' tables.
17
Explanatory footnotes to IFRS to core reconciliation tables
(1)Includes amortization for all intangible assets other than software.
(2) For the three and six months ended June 30, 2026, includes a post-tax, non-cash net charge of approximately $287 million related to the discontinuation of the PowerVision programs, including $505 million for the full impairment of an intangible asset, partially offset by $103 million for a fair value adjustment to contingent consideration liabilities and a $115 million tax benefit driven by the reversal of deferred tax liabilities.
(3) Includes impairment charges related to a currently marketed product intangible asset.
(4) For the six months ended June 30, 2025, includes gains on fair value remeasurements of investments in associated companies.
(5) For the three months ended June 30, 2025, Operating income includes $9 million of direct acquisition costs and $1 million of integration related costs related to acquisitions. Acquisition costs primarily include third party professional services for legal and due diligence fees. Integration related costs include third party professional services and accelerated equity-based compensation expense.
For the six months ended June 30, 2026, Gross profit includes the amortization of inventory fair value adjustments related to an acquisition. Operating income also includes $20 million of direct acquisition costs. Acquisition costs include third party professional services for legal fees and other transaction related costs.
For the six months ended June 30, 2025, Operating income includes $16 million of direct acquisition costs and $7 million of integration related costs related to acquisitions. Acquisition costs primarily include third party professional services for legal, banker, due diligence and accounting fees. Integration related costs include severance of $3 million, accelerated equity-based compensation expense of $3 million and third party professional services of $1 million.
(6) For the three and six months ended June 30, 2026, includes restructuring costs, third party consulting fees and other direct costs related to efficiency initiatives. These efficiency measures were announced in February 2026 and implementation is expected to be completed this year.
(7) For the three and six months ended June 30, 2025, includes provisions for legal matters.
(8) For the three and six months ended June 30, 2025, includes charges related to the discontinued commercialization of a product in the Vision Care reportable segment, including $43 million for the full impairment of the intangible asset and $1 million in related costs, primarily related to inventory provisions.
(9) For the three months ended June 30, 2026, Operating income includes the amortization of option rights, offset by fair value adjustments of financial assets.
For the six months ended June 30, 2026, Operating income includes the amortization of option rights, partially offset by fair value adjustments of financial assets.
For the six months ended June 30, 2025, Income before taxes includes core adjustments recognized for Aurion in Share of loss from associated companies. The expenses were incurred upon change in control from Alcon's acquisition of a majority interest in Aurion and include accelerated equity-based compensation expense of $2 million, third party professional services of $2 million for legal and accounting fees and third party bank fees of $1 million.
(10) For the three months ended June 30, 2026, total tax adjustments of $153 million include tax associated with operating income core adjustments and discrete tax items. Tax associated with operating income core adjustments of $563 million totaled $142 million with an average tax rate of 25.2%. Core tax adjustments for discrete tax items totaled $11 million.
For the three months ended June 30, 2025, total tax adjustments of $40 million include tax associated with operating income core adjustments, partially offset by discrete tax items. Tax associated with operating income core adjustments of $244 million totaled $48 million with an average tax rate of 19.7%. Core tax adjustments for discrete tax items totaled $8 million.
For the six months ended June 30, 2026, total tax adjustments of $204 million include tax associated with operating income core adjustments and discrete tax items. Tax associated with operating income core adjustments of $840 million totaled $192 million with an average tax rate of 22.9%. Core tax adjustments for discrete tax items totaled $12 million.
For the six months ended June 30, 2025, total tax adjustments of $73 million include tax associated with operating income core adjustments, partially offset by discrete tax items. Operating income core adjustments totaled $287 million. Excluding the non-taxable gain of $136 million on fair value remeasurement of Alcon's investment in Aurion, core adjustments to operating income totaled $423 million. The associated tax effect amounted to $81 million with an average tax rate of 19.1%. Core tax adjustments for discrete tax items totaled $8 million.
(11) Core basic earnings per share is calculated using core net income attributable to shareholders of Alcon Inc. and the weighted-average shares of common stock outstanding during the period. Core diluted earnings per share also contemplate dilutive shares associated with unvested equity-based awards as described in Note 4 to the Condensed Consolidated Interim Financial Statements.
18
EBITDA (non-IFRS measure)
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||||
| ($ millions) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||
| Net income | — | 176 | 189 | 526 | ||||||||||||||||
| Taxes | (46) | 23 | 5 | 87 | ||||||||||||||||
| Depreciation of property, plant & equipment | 111 | 103 | 219 | 201 | ||||||||||||||||
| Depreciation of right-of-use assets | 25 | 22 | 49 | 43 | ||||||||||||||||
| Amortization of intangible assets | 152 | 194 | 304 | 385 | ||||||||||||||||
| Impairments of property, plant & equipment and intangible assets | 505 | 43 | 543 | 43 | ||||||||||||||||
| Interest expense | 53 | 51 | 105 | 100 | ||||||||||||||||
| Other financial income & expense | — | (4) | (2) | (13) | ||||||||||||||||
| EBITDA | 800 | 608 | 1,412 | 1,372 | ||||||||||||||||
Cash flow and net (debt)/liquidity (non-IFRS measure)
| Six months ended June 30 | ||||||||||||||
| ($ millions) | 2026 | 2025 | ||||||||||||
| Net cash flows from operating activities | 928 | 889 | ||||||||||||
| Net cash flows used in investing activities | (440) | (732) | ||||||||||||
| Net cash flows used in financing activities | (643) | (479) | ||||||||||||
| Effect of exchange rate changes on cash and cash equivalents | (17) | 54 | ||||||||||||
| Net change in cash and cash equivalents | (172) | (268) | ||||||||||||
| Change in derivative financial instrument assets | 10 | (5) | ||||||||||||
| Change in time deposits with original maturity greater than three months | 21 | (153) | ||||||||||||
| Change in current and non-current financial debts | 18 | (102) | ||||||||||||
| Change in net (debt) | (123) | (528) | ||||||||||||
| Net (debt) at January 1 | (3,125) | (2,802) | ||||||||||||
| Net (debt) at June 30 | (3,248) | (3,330) | ||||||||||||
19
Net (debt)/liquidity (non-IFRS measure)
| ($ millions) | At June 30, 2026 | At December 31, 2025 | |||||||||
| Current financial debt | (570) | (575) | |||||||||
| Non-current financial debt | (4,149) | (4,162) | |||||||||
| Total financial debt | (4,719) | (4,737) | |||||||||
| Less liquidity: | |||||||||||
| Cash and cash equivalents | 1,355 | 1,527 | |||||||||
| Time deposits with original maturity greater than three months | 101 | 80 | |||||||||
| Derivative financial instruments | 15 | 5 | |||||||||
| Total liquidity | 1,471 | 1,612 | |||||||||
| Net (debt) | (3,248) | (3,125) | |||||||||
Free cash flow (non-IFRS measure)
The following is a summary of free cash flow for the six months ended June 30, 2026 and 2025, together with a reconciliation to net cash flows from operating activities, the most directly comparable IFRS measure:
| Six months ended June 30 | |||||||||||
| ($ millions) | 2026 | 2025 | |||||||||
| Net cash flows from operating activities | 928 | 889 | |||||||||
| Purchase of property, plant & equipment | (235) | (208) | |||||||||
| Free cash flow | 693 | 681 | |||||||||
20
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
Connect with us on 
Investor Relations
Daniel Cravens
Richard Bourne
+ 41 589 112 110 (Geneva)
+ 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Media Relations
Steven Smith
+ 41 589 112 111 (Geneva)
+ 1 817 551 8057 (Fort Worth)
globalmedia.relations@alcon.com
21
ALCON INC. INTERIM FINANCIAL REPORT
| INDEX | Page | ||||
| Operating Performance | |||||
| Liquidity and Capital Resources | |||||
Condensed Consolidated Interim Financial Statements of Alcon Inc. (unaudited) | |||||
| Consolidated Income Statement | |||||
| Consolidated Statement of Comprehensive (Loss)/Income | |||||
| Consolidated Balance Sheet | |||||
| Consolidated Statement of Changes in Equity | |||||
| Consolidated Statement of Cash Flows | |||||
Notes to Condensed Consolidated Interim Financial Statements of Alcon Inc. | |||||
| Disclaimer | |||||
1
OPERATING PERFORMANCE
Key figures
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||||||||||||||||
| ($ millions unless indicated otherwise) | 2026 | 2025 | Change % | 2026 | 2025 | Change % | ||||||||||||||||||||||||||
| Net sales | 2,782 | 2,577 | 8 | 5,467 | 5,028 | 9 | ||||||||||||||||||||||||||
| Gross profit | 1,675 | 1,388 | 21 | 3,200 | 2,771 | 15 | ||||||||||||||||||||||||||
| Operating income | 11 | 247 | (96) | 303 | 715 | (58) | ||||||||||||||||||||||||||
| Operating margin (%) | 0.4 | 9.6 | 5.5 | 14.2 | ||||||||||||||||||||||||||||
| Net income | — | 176 | (100) | 189 | 526 | (64) | ||||||||||||||||||||||||||
| Net income attributable to: | ||||||||||||||||||||||||||||||||
| Shareholders of Alcon Inc. | — | 176 | (100) | 189 | 526 | (64) | ||||||||||||||||||||||||||
| Non-controlling interests | — | — | — | — | — | — | ||||||||||||||||||||||||||
Basic earnings per share ($)(1) | 0.00 | 0.36 | (100) | 0.39 | 1.06 | (63) | ||||||||||||||||||||||||||
Diluted earnings per share ($)(1) | 0.00 | 0.35 | (100) | 0.39 | 1.06 | (63) | ||||||||||||||||||||||||||
(1)Earnings per share is calculated on the amount of net income attributable to shareholders of Alcon Inc. Per share amounts may not add across quarters due to rounding.
2
Net sales by segment
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||||||||||||||||
| ($ millions unless indicated otherwise) | 2026 | 2025 | Change % | 2026 | 2025 | Change % | ||||||||||||||||||||||||||
| Surgical | ||||||||||||||||||||||||||||||||
| Implantables | 466 | 456 | 2 | 904 | 876 | 3 | ||||||||||||||||||||||||||
| Consumables | 825 | 777 | 6 | 1,594 | 1,489 | 7 | ||||||||||||||||||||||||||
| Equipment/other | 279 | 222 | 26 | 532 | 421 | 26 | ||||||||||||||||||||||||||
| Total Surgical | 1,570 | 1,455 | 8 | 3,030 | 2,786 | 9 | ||||||||||||||||||||||||||
| Vision Care | ||||||||||||||||||||||||||||||||
| Contact lenses | 726 | 692 | 5 | 1,464 | 1,380 | 6 | ||||||||||||||||||||||||||
| Ocular health | 486 | 430 | 13 | 973 | 862 | 13 | ||||||||||||||||||||||||||
| Total Vision Care | 1,212 | 1,122 | 8 | 2,437 | 2,242 | 9 | ||||||||||||||||||||||||||
| Net sales | 2,782 | 2,577 | 8 | 5,467 | 5,028 | 9 | ||||||||||||||||||||||||||
Second quarter
Surgical
Surgical net sales were $1.6 billion, an increase of 8%, including favorable currency impacts of 1%.
•Implantables net sales were $466 million, an increase of 2%, including favorable currency impacts of 1%. This growth was driven by an increase in IOLs of 3%, primarily driven by the strong performance of PanOptix Pro and reflecting competitive pressures, partially offset by lower sales in surgical glaucoma.
•Consumables net sales were $825 million, an increase of 6%, including favorable currency impacts of 1%. Growth was driven by procedural growth and price increases with continued softness in the cataract market.
•Equipment/other net sales were $279 million, an increase of 26%, including favorable currency impacts of 1%. This growth was led by recent equipment launches, including the Unity platform.
Vision Care
Vision Care net sales were $1.2 billion, an increase of 8%, including favorable currency impacts of 1%.
•Contact lenses net sales were $726 million, an increase of 5%. This growth reflects product innovation and price increases, partially offset by declines in legacy products.
•Ocular health net sales were $486 million, an increase of 13%, including favorable currency impacts of 1%. Growth was led by our portfolio of dry eye products, including Tryptyr and Systane.
First half
Surgical
Surgical net sales were $3.0 billion, an increase of 9%, including favorable currency impacts of 2%.
•Implantables net sales were $904 million, an increase of 3%, including favorable currency impacts of 2%. This growth was driven by an increase in IOLs of 4%, primarily driven by the strong performance of PanOptix Pro and reflecting competitive pressures, partially offset by lower sales in surgical glaucoma.
•Consumables net sales were $1.6 billion, an increase of 7%, including favorable currency impacts of 2%. Growth was driven by procedural growth and price increases with continued softness in the cataract market.
•Equipment/other net sales were $532 million, an increase of 26%, including favorable currency impacts of 2%. This growth was led by recent equipment launches, including the Unity platform.
3
Vision Care
Vision Care net sales were $2.4 billion, an increase of 9%, including favorable currency impacts of 2%.
•Contact lenses net sales were $1.5 billion, an increase of 6%, including favorable currency impacts of 2%. This growth reflects product innovation and price increases, partially offset by declines in legacy products.
•Ocular health net sales were $973 million, an increase of 13%, including favorable currency impacts of 2%. Growth was led by our portfolio of dry eye products, including Tryptyr and Systane.
4
Operating income
| Three months ended June 30 | Six months ended June 30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| ($ millions unless indicated otherwise) | 2026 | 2025 | Change % | 2026 | 2025 | Change % | |||||||||||||||||||||||||||||||||||||||||||||||
| Cost of net sales | (1,130) | (1,196) | 6 | (2,293) | (2,267) | (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Gross profit | 1,675 | 1,388 | 21 | 3,200 | 2,771 | 15 | |||||||||||||||||||||||||||||||||||||||||||||||
| Gross margin (%) | 60.2 | 53.9 | 58.5 | 55.1 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Selling, general & administration | (964) | (870) | (11) | (1,846) | (1,683) | (10) | |||||||||||||||||||||||||||||||||||||||||||||||
| Research & development | (663) | (245) | (171) | (908) | (467) | (94) | |||||||||||||||||||||||||||||||||||||||||||||||
| Other income | 6 | 5 | 20 | 17 | 154 | (89) | |||||||||||||||||||||||||||||||||||||||||||||||
| Other expense | (43) | (31) | (39) | (160) | (60) | (167) | |||||||||||||||||||||||||||||||||||||||||||||||
| Operating income | 11 | 247 | (96) | 303 | 715 | (58) | |||||||||||||||||||||||||||||||||||||||||||||||
| Operating margin (%) | 0.4 | 9.6 | 5.5 | 14.2 | |||||||||||||||||||||||||||||||||||||||||||||||||
Second quarter
Operating income was $11 million (-96%), compared to $247 million in the prior year period. Operating margin decreased 9.2 percentage points. The current year period included an impairment charge of $505 million, partially offset by $103 million for a fair value adjustment to contingent consideration liabilities, related to the discontinuation of the IOL programs acquired from PowerVision, Inc. in March 2019 ("PowerVision programs"), costs associated with efficiency measures and sales and marketing behind new product launches, partially offset by lower amortization, manufacturing efficiencies, $15 million of other revenue from a licensee and a positive 0.1 percentage point impact from currency. The prior year period included charges related to the discontinued commercialization of a Vision Care product and higher inventory-related costs.
First half
Operating income was $303 million (-58%), compared to $715 million in the prior year period. Operating margin decreased 8.7 percentage points. The current year period included an impairment charge of $505 million, partially offset by $103 million for a fair value adjustment to contingent consideration liabilities, related to the discontinuation of the PowerVision programs, costs associated with efficiency measures, sales and marketing behind new product launches, impairment charges related to a currently marketed product intangible asset and incremental tariffs, partially offset by lower amortization, manufacturing efficiencies and a positive 0.4 percentage point impact from currency. The prior year period included gains on fair value remeasurements of investments in associated companies, partially offset by charges related to the discontinued commercialization of a Vision Care product.
5
Segment contribution
For additional information regarding segment contribution, please refer to Note 3 to the Condensed Consolidated Interim Financial Statements.
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||||||||||||||||
| ($ millions unless indicated otherwise) | 2026 | 2025 | Change % | 2026 | 2025 | Change % | ||||||||||||||||||||||||||
| Surgical segment contribution | 392 | 378 | 4 | 759 | 714 | 6 | ||||||||||||||||||||||||||
| As % of net sales | 25.0 | 26.0 | 25.0 | 25.6 | ||||||||||||||||||||||||||||
| Vision Care segment contribution | 283 | 208 | 36 | 577 | 489 | 18 | ||||||||||||||||||||||||||
| As % of net sales | 23.3 | 18.5 | 23.7 | 21.8 | ||||||||||||||||||||||||||||
| Not allocated to segments | (664) | (339) | (96) | (1,033) | (488) | (112) | ||||||||||||||||||||||||||
| Operating income | 11 | 247 | (96) | 303 | 715 | (58) | ||||||||||||||||||||||||||
Second quarter
Surgical
Surgical segment contribution was $392 million (+4%), compared to $378 million in the prior year period. Segment contribution margin decreased 1.0 percentage points, primarily driven by unfavorable product mix, incremental tariffs and sales and marketing behind new product launches, partially offset by a positive 0.3 percentage point impact from currency. The prior year period included higher inventory-related costs.
Vision Care
Vision Care segment contribution was $283 million (+36%), compared to $208 million in the prior year period. Segment contribution margin increased 4.8 percentage points, primarily due to manufacturing efficiencies, $15 million of other revenue from a licensee, lower impact from tariffs, favorable product mix and price increases. The increase in segment contribution margin was partially offset by increased investment in research and development, sales and marketing behind new product launches and a negative 0.4 percentage point impact from currency.
Not allocated to segments
Operating loss not allocated to segments totaled $664 million (-96%), compared to $339 million in the prior year period. The current year period included an impairment charge of $505 million, partially offset by $103 million for a fair value adjustment to contingent consideration liabilities, related to the discontinuation of the PowerVision programs. The prior year period included higher amortization of intangible assets and $44 million of product discontinuation charges.
First half
Surgical
Surgical segment contribution was $759 million (+6%), compared to $714 million in the prior year period. Segment contribution margin decreased 0.6 percentage points, primarily driven by unfavorable product mix, sales and marketing behind new product launches and incremental tariffs, partially offset by a positive 0.3 percentage point impact from currency.
Vision Care
Vision Care segment contribution was $577 million (+18%), compared to $489 million in the prior year period. Segment contribution margin increased 1.9 percentage points, primarily due to manufacturing efficiencies, price increases and $15 million of other revenue from a licensee. The increase in segment contribution margin was partially offset by increased investment in research and development, sales and marketing behind new product launches, and a negative 0.2 percentage point impact from currency.
6
Not allocated to segments
Operating loss not allocated to segments totaled $1.0 billion (-112%), compared to $488 million in the prior year period. The current year period included an impairment charge of $505 million, partially offset by $103 million for a fair value adjustment to contingent consideration liabilities, related to the discontinuation of the PowerVision programs, $121 million of costs associated with efficiency measures and $38 million of impairment charges related to a currently marketed product intangible asset. The prior year period included gains of $142 million on fair value remeasurements of investments in associated companies, partially offset by higher amortization of intangible assets and $44 million of product discontinuation charges.
7
Non-operating income & expense
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||||||||||||||||
| ($ millions unless indicated otherwise) | 2026 | 2025 | Change % | 2026 | 2025 | Change % | ||||||||||||||||||||||||||
| Operating income | 11 | 247 | (96) | 303 | 715 | (58) | ||||||||||||||||||||||||||
| Interest expense | (53) | (51) | (4) | (105) | (100) | (5) | ||||||||||||||||||||||||||
| Other financial income & expense | — | 4 | (100) | 2 | 13 | (85) | ||||||||||||||||||||||||||
| Share of loss from associated companies | (4) | (1) | (300) | (6) | (15) | 60 | ||||||||||||||||||||||||||
| (Loss)/income before taxes | (46) | 199 | nm | 194 | 613 | (68) | ||||||||||||||||||||||||||
| Taxes | 46 | (23) | nm | (5) | (87) | 94 | ||||||||||||||||||||||||||
| Net income | — | 176 | (100) | 189 | 526 | (64) | ||||||||||||||||||||||||||
| Net income attributable to: | ||||||||||||||||||||||||||||||||
| Shareholders of Alcon Inc. | — | 176 | (100) | 189 | 526 | (64) | ||||||||||||||||||||||||||
| Non-controlling interests | — | — | — | — | — | — | ||||||||||||||||||||||||||
Basic earnings per share ($)(1) | 0.00 | 0.36 | (100) | 0.39 | 1.06 | (63) | ||||||||||||||||||||||||||
Diluted earnings per share ($)(1) | 0.00 | 0.35 | (100) | 0.39 | 1.06 | (63) | ||||||||||||||||||||||||||
nm = not meaningful
(1) Earnings per share is calculated on the amount of net income attributable to shareholders of Alcon Inc. Per share amounts may not add across quarters due to rounding.
Second quarter
Interest expense
Interest expense was $53 million, broadly in line with the prior year period.
Other financial income & expense
Other financial income & expense was $0 million, compared to a net benefit of $4 million in the prior year period, primarily driven by an increase in foreign currency exchange losses.
Share of loss from associated companies
Share of loss from associated companies was $4 million, compared to $1 million in the prior year period, reflecting Alcon's investment in associated companies during the year.
Taxes
There was a tax benefit of $46 million in the current year period, compared to a tax expense of $23 million in the prior year period. The current year tax benefit was primarily driven by the reversal of deferred tax liabilities of $115 million related to the discontinuation of the PowerVision programs. The prior year period included a more favorable mix of pre-tax income/(loss) across geographical tax jurisdictions and a net benefit from discrete tax items.
Net income and earnings per share
Net income attributable to shareholders of Alcon Inc. was $0 million, compared to $176 million in the prior year period, primarily as a result of a post-tax, non-cash net charge of approximately $287 million related to the discontinuation of the PowerVision programs. The associated basic and diluted earnings per share were $0.00, compared to basic and diluted earnings per share of $0.36 and $0.35, respectively, in the prior year period.
First half
Interest expense
Interest expense was $105 million, compared to $100 million in the prior year period, primarily driven by higher interest expense from accretion of long-term contingent consideration liabilities and higher interest expense on lease liabilities.
Other financial income & expense
Other financial income & expense was a net benefit of $2 million, compared to $13 million in the prior year period, primarily driven by lower interest income and an increase in foreign currency exchange losses.
8
Share of loss from associated companies
Share of loss from associated companies was $6 million, compared to $15 million in the prior year period, reflecting Alcon's investment in associated companies during the year.
Taxes
Tax expense was $5 million, compared to $87 million in the prior year period. The average tax rate was 2.6%, compared to 14.2% in the prior year period. The average tax rate in the current year period was impacted by a $115 million tax benefit from the reversal of deferred tax liabilities related to the discontinuation of the PowerVision programs. The average tax rate in the prior year period included a non-taxable gain on the fair value remeasurement of an investment in an associated company and net benefits from discrete tax items.
Net income and earnings per share
Net income attributable to shareholders of Alcon Inc. was $189 million, compared to $526 million in the prior year period, primarily due to a post-tax, non-cash net charge of approximately $287 million related to the discontinuation of the PowerVision programs and costs associated with efficiency measures. The prior year period included gains of $142 million on fair value remeasurements of investments in associated companies. The associated basic and diluted earnings per share were $0.39, compared to basic and diluted earnings per share of $1.06 in the prior year period.
9
LIQUIDITY AND CAPITAL RESOURCES
Cash flow
Net cash flows from operating activities
Net cash flows from operating activities amounted to $928 million in the first six months of 2026, compared to $889 million in the prior year period. The current year period reflects increased collections associated with higher sales, lower associate short-term incentive payments, partially offset by increased payments for operating expenses, including sales and marketing behind new product launches, incremental tariffs, increased research and development, higher payments for revenue deductions and a higher impact from changes in net working capital. In addition, the current year period included payments associated with efficiency measures announced in February 2026.
Changes in net working capital in the current year period were mainly driven by increases in inventories and trade receivables, the net change in other operating assets and the net change in other operating liabilities, partially offset by an increase in trade payables. The increase in inventories was primarily to meet expected upcoming demand and the increase in trade receivables was primarily driven by new receivables from higher sales outpacing collections. The net change in other operating assets was primarily driven by increases in prepaid expenses and long-term receivables. The net change in other operating liabilities was primarily due to the impact of annual short-term incentive payments. The increase in trade payables was primarily driven by the timing of payments and raw materials purchases.
Changes in net working capital in the prior year period were mainly driven by an increase in trade receivables, the net change in other operating liabilities and an increase in inventories, partially offset by an increase in trade payables. The increase in trade receivables was primarily driven by new receivables from higher sales outpacing collections. The net change in other operating liabilities was primarily driven by the timing of annual associate short-term incentive payments, and were higher than in the current year period. The increase in inventories was primarily to meet expected upcoming demand. The increase in trade payables was primarily driven by the timing of payments and raw materials purchases.
Net cash flows used in investing activities
Net cash flows used in investing activities amounted to $440 million in the first six months of 2026, compared to $732 million in the prior year period. Cash outflows in the current year period primarily include capital expenditures, purchases of intangible assets, the purchase of a time deposit in the second quarter of 2026 and payments for financial assets, partially offset by proceeds from a time deposit which matured in April 2026.
Cash outflows in the prior year period primarily included the acquisition of a majority interest in Aurion Biotech, Inc. ("Aurion"), the acquisition of Cylite Pty Ltd. ("Cylite"), capital expenditures and purchases of intangible assets, primarily related to software, partially offset by proceeds from a time deposit which matured in February 2025. Refer to Note 12 to the Condensed Consolidated Interim Financial Statements for additional information on the Aurion and Cylite transactions.
Net cash flows used in financing activities
Net cash flows used in financing activities amounted to $643 million in the first six months of 2026, compared to $479 million in the prior year period. Cash outflows in the current year period primarily include payments for the acquisition of treasury shares, dividends paid to shareholders of Alcon Inc., withholding taxes paid upon net settlements of equity-based compensation, lease payments and realized foreign exchange losses.
Cash outflows in the prior year period primarily included dividends paid to shareholders of Alcon Inc., payments for the acquisition of treasury shares, realized foreign exchange losses, withholding taxes paid upon net settlements of equity-based compensation and lease payments.
Balance sheet
Assets
Total non-current assets were $24.5 billion as of June 30, 2026, a decrease of $632 million when compared to $25.1 billion as of December 31, 2025. Intangible assets other than goodwill decreased $736 million primarily due to asset impairments, including a $505 million impairment related to the discontinuation of the PowerVision programs, and recurring amortization, partially offset by additions.
10
Total current assets were $6.6 billion as of June 30, 2026, an increase of $175 million when compared to $6.4 billion as of December 31, 2025. Trade receivables increased $137 million due to higher sales outpacing collections, partially offset by foreign currency translation effects. Inventories increased $119 million primarily due to increases to meet expected upcoming demand, partially offset by foreign currency translation effects. Cash and cash equivalents decreased $172 million due to the net impact of operating, investing and financing activities as described in the preceding section. Our cash and cash equivalents are maintained at a number of financial institutions. To mitigate the risk of uninsured balances, we select financial institutions based on their credit ratings and financial strength, and we perform ongoing evaluations of these institutions to limit our concentration risk exposure.
Liabilities
Total non-current liabilities were $6.3 billion as of June 30, 2026, a decrease of $136 million when compared to $6.5 billion as of December 31, 2025. Deferred tax liabilities decreased $100 million primarily related to the release of deferred tax liabilities associated with the discontinuation of the PowerVision programs. Provisions & other non-current liabilities decreased $93 million primarily due to a fair value adjustment to contingent consideration liabilities associated with the discontinuation of the PowerVision programs.
Total current liabilities were $3.2 billion as of June 30, 2026, an increase of $118 million when compared to $3.0 billion as of December 31, 2025.
The average maturity of financial debts outstanding as of June 30, 2026 is 8.3 years, and 97% of Alcon's financial debt is at fixed interest rates. We believe that we have adequate liquidity to meet our needs.
The $1.32 billion revolving credit facility remained undrawn as of June 30, 2026 and August 10, 2026.
Equity
Equity was $21.6 billion as of June 30, 2026, a decrease of $439 million when compared to $22.0 billion as of December 31, 2025.
11
Additional Considerations
Terminated Acquisition of LENSAR, Inc.
On March 23, 2025, Alcon entered into a definitive agreement to acquire all outstanding shares of LENSAR, Inc. ("LENSAR"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, with a total consideration of up to approximately $430 million. On March 16, 2026, Alcon entered into an agreement with LENSAR to terminate the previously announced merger agreement.
Conflicts in the Middle East
Ongoing geopolitical conflicts in the Middle East have contributed to increased regional and global political and economic uncertainty. These conflicts, together with related government actions, sanctions, trade restrictions, and retaliatory measures, could adversely impact net sales, create disruptions in global supply chains, increase the risk of cyber attacks, and potentially have an adverse effect on the global economy, financial markets, energy markets, commodity prices, currency exchange rates, and otherwise. As a result of broader global impacts, we have experienced, and may continue to experience, volatility in currency translation effects.
For the six months ended June 30, 2026, net sales in countries impacted within the Middle East region were approximately 2% of consolidated net sales. As of June 30, 2026, our operations in the region continued operating to the extent practicable and permitted by law.
Efficiency Measures
On February 24, 2026, Alcon announced certain efficiency measures supported by operational improvements and infrastructure investments. Alcon estimates the total cost to implement these efficiency measures to be approximately $150 million and expects the implementation to be completed in 2026. Related expenses totaled $33 million and $121 million for the three and six months ended June 30, 2026, respectively.
Tariffs
Beginning in February 2025, the United States government announced additional tariffs on goods imported into the United States, and some nations have responded with retaliatory tariffs and other actions on U.S. products. Global trade policy continues to evolve and the ultimate impact of developments with respect to U.S. tariffs remains unclear. On February 20, 2026, the U.S. Supreme Court struck down one set of tariffs (i.e., the tariffs imposed under the International Emergency Economic Powers Act ("IEEPA")). As a result of this ruling, importers may be entitled to recover IEEPA-based tariffs. Immediately following the Supreme Court's ruling, the U.S. government imposed a temporary 10% global tariff on most imports effective February 24, 2026 under Section 122 of the Trade Act of 1974, which was valid for up to 150 days and expired on July 24, 2026. Immediately after the Section 122 tariffs expired, the U.S. government imposed new tariffs under Section 301 of the Trade Act of 1974, which imposes tariffs ranging from 10% to 12.5% on imports from 86 countries.
Furthermore, following the Supreme Court's decision, the U.S. Court of International Trade ("CIT") subsequently ordered the U.S. Customs and Border Protection ("CBP") to issue refunds to importers who paid IEEPA tariffs. To respond to the CIT's order, the CBP created the Consolidated Administration and Processing for Entries ("CAPE") framework to process IEEPA tariff refund requests. The CAPE framework only provides a refund mechanism for certain entries on which IEEPA tariffs were paid. In June 2026, the U.S. Department of Justice appealed the portion of the CIT order that required the government to refund IEEPA tariffs on entries that have liquidated and become final (i.e., entries liquidated for more than 90 days) for non-participants in the underlying CIT litigation.
The total amount Alcon paid in IEEPA tariffs as of June 30, 2026 is approximately $64 million. As of June 30, 2026, Alcon submitted a refund claim through the CAPE framework for certain IEEPA tariffs. The timing, amount and ultimate realization of any refunds was uncertain and subject to governmental processes as of June 30, 2026. As a result, Alcon has not recorded any potential refunds on the Condensed Consolidated Balance Sheet as of June 30, 2026. After June 30, 2026 and as of August 10, 2026, the CBP completed its review of certain import entries encompassed by Alcon's IEEPA refund claim and has begun transmitting refunds. The timing, amount, and ultimate realization of any remaining IEEPA refunds is uncertain.
Tariffs incurred in the United States under IEEPA and Section 122 and in China during the six months ended June 30, 2026 amounted to $39 million, which was recognized in Cost of net sales in the Condensed Consolidated Income Statement.
12
The future effects of the above-referenced tariffs, along with any further changes in trade policies including additional tariffs, are uncertain and could have an adverse effect on our business, financial condition, cash flows and results of operations. Further, adverse economic conditions impacting our customers or uncertainty about global economic conditions could cause purchases of our products to decline, which would adversely affect our net sales and operating results.
Refer to “Item 3. Key Information—3.D. Risk Factors—Changing economic and financial environments in many countries and increasing global political and social instability may adversely impact our business” in the 2025 form 20-F.
Share repurchase authorization
On May 5, 2026, the Alcon Board of Directors authorized the repurchase of up to $1.5 billion of the Company’s common shares, par value of CHF 0.04 per share, on a second trading line with the SIX Swiss Exchange. The shares to be acquired under this share buyback program will be cancelled as a return of capital to shareholders.
Alcon expects to fund the program through cash generated from operations. The program is subject to customary safe harbor conditions and authorization of the Swiss Takeover Board. The timing and total amount of share repurchases and cancellations will depend upon a variety of factors. The program is expected to be completed over a three-year period, but may be suspended or discontinued at any time. Refer to Note 4 to the Condensed Consolidated Interim Financial Statements for details on share repurchase activity for the six months ended June 30, 2026.
Discontinuation of the PowerVision programs
In August 2026, following the review of the latest clinical study data, Alcon made the decision to discontinue the PowerVision programs. Alcon considered the decision to discontinue the PowerVision programs to be an impairment indicator as of June 30, 2026 for the related intangible asset and, as a result of the impairment assessment, recorded a non-cash impairment charge of $505 million, representing the asset's full carrying value, in Research & development in the Condensed Consolidated Income Statement. The discontinuation of the PowerVision programs also resulted in a fair value adjustment of $103 million to contingent consideration liabilities in Provisions & other non-current liabilities and recognized in Research & development in the Condensed Consolidated Income Statement. In addition, there was a $115 million reversal of Deferred tax liabilities and recognized in Taxes in the Condensed Consolidated Income Statement. Refer to Note 5 and 7 to the Condensed Consolidated Interim Financial Statements for details.
Foreign currencies
We use the US Dollar as our reporting currency and are therefore also exposed to foreign currency exchange movements and costs to enter hedging agreements, primarily in Euros, Japanese Yen, Chinese Renminbi, Canadian Dollars, Singaporean Dollars, Swiss Francs, Russian Rubles and emerging market currencies. The foreign currency exposure on the balance sheet is hedged with limited exception, but the impact of ongoing macroeconomic conditions is currently unknown and could have a material adverse effect on our results of operations, cash flows or financial condition.
13
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS OF ALCON INC.
Consolidated Income Statement (unaudited)
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||||
| ($ millions except earnings per share) | Note | 2026 | 2025 | 2026 | 2025 | |||||||||||||||
| Net sales | 3 | |||||||||||||||||||
| Other revenues | 3 | |||||||||||||||||||
| Net sales and other revenues | ||||||||||||||||||||
| Cost of net sales | ( | ( | ( | ( | ||||||||||||||||
| Cost of other revenues | ( | ( | ( | ( | ||||||||||||||||
| Gross profit | ||||||||||||||||||||
| Selling, general & administration | ( | ( | ( | ( | ||||||||||||||||
| Research & development | ( | ( | ( | ( | ||||||||||||||||
| Other income | ||||||||||||||||||||
| Other expense | ( | ( | ( | ( | ||||||||||||||||
| Operating income | ||||||||||||||||||||
| Interest expense | ( | ( | ( | ( | ||||||||||||||||
| Other financial income & expense | ||||||||||||||||||||
| Share of loss from associated companies | 13 | ( | ( | ( | ( | |||||||||||||||
| (Loss)/income before taxes | ( | |||||||||||||||||||
| Taxes | ( | ( | ( | |||||||||||||||||
| Net income | ||||||||||||||||||||
| Net income attributable to: | ||||||||||||||||||||
| Shareholders of Alcon Inc. | ||||||||||||||||||||
| Non-controlling interests | ||||||||||||||||||||
Earnings per share ($)(1) | ||||||||||||||||||||
Basic | ||||||||||||||||||||
Diluted | ||||||||||||||||||||
| Weighted average number of shares outstanding (millions) | ||||||||||||||||||||
| Basic | 4 | |||||||||||||||||||
| Diluted | 4 | |||||||||||||||||||
(1) Earnings per share is calculated on the amount of net income attributable to shareholders of Alcon Inc.
The accompanying Notes form an integral part of the Condensed Consolidated Interim Financial Statements.
14
Consolidated Statement of Comprehensive (Loss)/Income (unaudited)
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||||
| ($ millions) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||
| Net income | ||||||||||||||||||||
| Other comprehensive income to be eventually recycled into the Consolidated Income Statement: | ||||||||||||||||||||
Currency translation effects, net of taxes(1) | ( | ( | ||||||||||||||||||
| Total of items to eventually recycle | ( | ( | ||||||||||||||||||
| Other comprehensive income never to be recycled into the Consolidated Income Statement: | ||||||||||||||||||||
Actuarial gains/(losses) from defined benefit plans, net of taxes(2) | ( | |||||||||||||||||||
Fair value adjustments on equity investments, net of taxes(3) | ( | ( | ||||||||||||||||||
| Total of items never to be recycled | ( | ( | ||||||||||||||||||
| Total comprehensive (loss)/income | ( | |||||||||||||||||||
| Total comprehensive (loss)/income for the period attributable to: | ||||||||||||||||||||
| Shareholders of Alcon Inc. | ( | |||||||||||||||||||
| Non-controlling interests | ||||||||||||||||||||
(1)Amount is net of tax benefit of $0.5 million for the three months ended June 30, 2026. Amount is net of tax expense of $2 million for the three months ended June 30, 2025. Amount is net of tax benefit of $2 million for the six months ended June 30, 2026. Amount is net of tax expense of $3 million for the six months ended June 30, 2025.
(2)Amount is net of tax expense of $0.6 million for the three months ended June 30, 2026. Amount is net of tax benefit of $0.6 million for the three months ended June 30, 2025. Amounts are net of tax expense of $2 million and $1 million for the six months ended June 30, 2026 and 2025, respectively.
(3)Amount is net of tax benefit of $10 million for the three months ended June 30, 2026. Amount is net of tax expense of $8 million for the three months ended June 30, 2025. Amount is net of tax benefit of $10 million for the six months ended June 30, 2026. Amount is net of tax expense of $10 million for the six months ended June 30, 2025.
The accompanying Notes form an integral part of the Condensed Consolidated Interim Financial Statements.
15
Consolidated Balance Sheet (unaudited)
| ($ millions) | Note | June 30, 2026 | December 31, 2025 | ||||||||
| Assets | |||||||||||
| Non-current assets | |||||||||||
| Property, plant & equipment | |||||||||||
| Right-of-use assets | |||||||||||
| Goodwill | |||||||||||
| Intangible assets other than goodwill | 5 | ||||||||||
| Deferred tax assets | |||||||||||
| Financial assets | 7 | ||||||||||
| Other non-current assets | |||||||||||
| Total non-current assets | |||||||||||
| Current assets | |||||||||||
| Inventories | |||||||||||
| Trade receivables | |||||||||||
| Income tax receivables | |||||||||||
| Cash and cash equivalents | |||||||||||
| Time deposits | 7 | ||||||||||
| Other current assets | |||||||||||
| Total current assets | |||||||||||
| Total assets | |||||||||||
| Equity and liabilities | |||||||||||
| Equity | |||||||||||
| Share capital | |||||||||||
| Reserves | |||||||||||
| Equity attributable to shareholders of Alcon Inc. | |||||||||||
| Non-controlling interests | |||||||||||
| Total equity | |||||||||||
| Liabilities | |||||||||||
| Non-current liabilities | |||||||||||
| Financial debts | 6 | ||||||||||
| Lease liabilities | |||||||||||
| Deferred tax liabilities | |||||||||||
| Provisions & other non-current liabilities | |||||||||||
| Total non-current liabilities | |||||||||||
| Current liabilities | |||||||||||
| Trade payables | |||||||||||
| Financial debts | 6 | ||||||||||
| Lease liabilities | |||||||||||
| Current income tax liabilities | |||||||||||
| Provisions & other current liabilities | |||||||||||
| Total current liabilities | |||||||||||
| Total liabilities | |||||||||||
| Total equity and liabilities | |||||||||||
The accompanying Notes form an integral part of the Condensed Consolidated Interim Financial Statements.
16
Consolidated Statement of Changes in Equity (unaudited)
Six months ended June 30, 2026
| Attributable to shareholders of Alcon Inc. | |||||||||||||||||||||||||||||
| ($ millions) | Share capital | Other reserves | Fair value adjustments on equity investments | Actuarial gains from defined benefit plans | Cumulative currency translation effects | Total value adjustments(1) | Total | Non-controlling interests | Total equity | ||||||||||||||||||||
| Balance as of January 1, 2026 | ( | ||||||||||||||||||||||||||||
| Net income | — | — | |||||||||||||||||||||||||||
| Other comprehensive income/(loss) | ( | ( | ( | ( | — | ( | |||||||||||||||||||||||
| Total comprehensive income | — | ( | ( | ( | — | ||||||||||||||||||||||||
| Dividends | ( | — | ( | — | ( | ||||||||||||||||||||||||
| Acquisition of treasury shares | ( | — | ( | — | ( | ||||||||||||||||||||||||
| Equity-based compensation | — | — | |||||||||||||||||||||||||||
Other movements(2) | — | ||||||||||||||||||||||||||||
| Total other movements | — | ( | — | — | ( | ( | |||||||||||||||||||||||
| Balance as of June 30, 2026 | ( | ( | ( | ||||||||||||||||||||||||||
Six months ended June 30, 2025
| Attributable to shareholders of Alcon Inc. | |||||||||||||||||||||||||||||
| ($ millions) | Share capital | Other reserves | Fair value adjustments on equity investments | Actuarial gains from defined benefit plans | Cumulative currency translation effects | Total value adjustments(1) | Total | Non-controlling interests | Total equity | ||||||||||||||||||||
| Balance as of January 1, 2025 | ( | ( | ( | ||||||||||||||||||||||||||
| Net income | — | — | |||||||||||||||||||||||||||
| Other comprehensive income | — | ||||||||||||||||||||||||||||
| Total comprehensive income | — | — | |||||||||||||||||||||||||||
| Dividends | ( | — | ( | — | ( | ||||||||||||||||||||||||
| Acquisition of treasury shares | ( | — | ( | — | ( | ||||||||||||||||||||||||
| Equity-based compensation | — | — | |||||||||||||||||||||||||||
| Initial recognition of non-controlling interests | — | — | |||||||||||||||||||||||||||
| Changes in non-controlling interests | — | — | ( | ( | |||||||||||||||||||||||||
Other movements(2) | ( | ( | — | ||||||||||||||||||||||||||
| Total other movements | — | ( | ( | — | — | ( | ( | ( | |||||||||||||||||||||
| Balance as of June 30, 2025 | ( | ||||||||||||||||||||||||||||
(1) "Total value adjustments" are presented net of the corresponding tax effects.
(2)Activity includes hyperinflationary accounting. For the six months ended June 30, 2025, Other reserves also includes the reversal of previously-recognized deferred tax and a reclassification related to the settlement of an equity investment.
The accompanying Notes form an integral part of the Condensed Consolidated Interim Financial Statements.
17
Consolidated Statement of Cash Flows (unaudited)
| Six months ended June 30 | ||||||||||||||
| ($ millions) | Note | 2026 | 2025 | |||||||||||
| Net income | ||||||||||||||
| Adjustments to reconcile net income to net cash flows from operating activities | ||||||||||||||
| Depreciation, amortization, impairments and fair value adjustments | 8.1 | |||||||||||||
| Equity-based compensation expense | ||||||||||||||
| Non-cash change in current and non-current provisions and other non-current liabilities | ||||||||||||||
| Losses on disposal and other adjustments on property, plant & equipment and other non-current assets, net | ||||||||||||||
| Interest expense | ||||||||||||||
| Other financial income & expense | ( | ( | ||||||||||||
| Share of loss from associated companies | 13 | |||||||||||||
| Taxes | ||||||||||||||
| Interest received | ||||||||||||||
| Interest paid | ( | ( | ||||||||||||
| Other financial payments | ( | ( | ||||||||||||
| Taxes paid | ( | ( | ||||||||||||
| Net cash flows before working capital changes and net payments out of provisions and other non-current liabilities | ||||||||||||||
| Net payments out of provisions and other cash movements in non-current liabilities | ( | ( | ||||||||||||
| Change in net current assets and other operating cash flow items | 8.2 | ( | ( | |||||||||||
| Net cash flows from operating activities | ||||||||||||||
| Purchase of property, plant & equipment | ( | ( | ||||||||||||
| Purchase of intangible assets | ( | ( | ||||||||||||
| Purchase of investments in associated companies | 13 | ( | ||||||||||||
| Payments for financial assets | ( | ( | ||||||||||||
| Purchase of time deposits | 7 | ( | ||||||||||||
| Proceeds from time deposits | ||||||||||||||
| Proceeds from financial assets | ||||||||||||||
| Acquisitions of businesses, net of cash acquired | 12 | ( | ||||||||||||
| Other investing cash flows | ( | |||||||||||||
| Net cash flows used in investing activities | ( | ( | ||||||||||||
| Dividends paid to shareholders of Alcon Inc. | 4 | ( | ( | |||||||||||
| Repayment of financial debts | ( | ( | ||||||||||||
| Proceeds from financial debts, net of issuance costs | ||||||||||||||
| Other net changes in financial debts | ||||||||||||||
| Payments for acquisition of treasury shares | 4 | ( | ( | |||||||||||
| Lease payments | ( | ( | ||||||||||||
| Payment of withholding taxes related to equity-based compensation | ( | ( | ||||||||||||
| Transactions with non-controlling interests | ( | |||||||||||||
| Other financing cash flows | ( | ( | ||||||||||||
| Net cash flows used in financing activities | ( | ( | ||||||||||||
| Effect of exchange rate changes on cash and cash equivalents | ( | |||||||||||||
| Net change in cash and cash equivalents | ( | ( | ||||||||||||
| Cash and cash equivalents at January 1 | ||||||||||||||
| Cash and cash equivalents at June 30 | ||||||||||||||
The accompanying Notes form an integral part of the Condensed Consolidated Interim Financial Statements.
18
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS OF ALCON INC. (unaudited)
1. Selected accounting policies
Basis of preparation
These Condensed Consolidated Interim Financial Statements for Alcon Inc. ("the Company") and the subsidiaries it controls (collectively, "Alcon") have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB") and with the accounting policies as described in Note 2 to the December 31, 2025 Consolidated Financial Statements in the Company’s 2025 Form 20-F ("Form 20-F").
These Condensed Consolidated Interim Financial Statements do not include all of the information required for a complete set of International Financial Reporting Standards ("IFRS") financial statements. The financial information consolidates the Company and the subsidiaries it controls, and includes selected notes to explain events and transactions that are significant to an understanding of the changes in Alcon's financial position and performance since the prior annual Consolidated Financial Statements. For non-wholly owned subsidiaries, non-controlling interests are recognized to reflect the portion of equity that is not attributable, directly or indirectly, to shareholders of the Company. The Condensed Consolidated Interim Financial Statements should be read in conjunction with the annual Consolidated Financial Statements for the year ended December 31, 2025, which have been prepared in accordance with IFRS as issued by the IASB ("IFRS Accounting Standards") and can be found in the Form 20-F.
Use of estimates and assumptions
The preparation of Condensed Consolidated Interim Financial Statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the period, that affect the reported amounts of assets and liabilities as well as revenues and expenses. Because of the inherent uncertainties, actual outcomes and results may differ from management's assumptions and estimates.
Impairment of goodwill, Alcon brand name and definite lived intangible assets
As discussed in Note 2 to the Consolidated Financial Statements in the Form 20-F, Goodwill, the Alcon brand name and acquired in-process research & development ("IPR&D") projects are reviewed for impairment at least annually and these, as well as all other investments in intangible assets, are reviewed for impairment whenever events or changes in circumstance indicate that the asset's balance sheet or reportable segment carrying amount may not be recoverable. Goodwill and other intangible assets represent a significant amount of total assets on the Consolidated Balance Sheet. Impairment testing may lead to potentially significant impairment charges in the future, which could have a materially adverse impact on Alcon's results of operations and financial condition.
19
New standards and interpretations not yet adopted
In April 2024, the IASB issued IFRS 18, Presentation and Disclosure in Financial Statements, which will replace IAS 1, Presentation of Financial Statements and accompanies limited amendments to other standards which will be effective upon the adoption of the new standard. IFRS 18 will be retroactively effective for our annual reporting periods beginning on January 1, 2027, with early adoption permitted. The standard is expected to improve comparability and transparency of financial statements by requiring five categories (operating, investing, financing, income taxes and discontinued operations) and defined subtotals and totals ("operating profit or loss", "profit or loss before financing and income taxes" and "profit or loss") in the Consolidated Income Statement, requiring disclosures in the notes to the financial statements about management-defined performance measures and adding new principles for aggregation and disaggregation of information in the primary financial statements and notes. IFRS 18 will not impact recognition or measurement of the financial statement items. However, it may impact operating income due to the reclassification of certain income and expense items within the five categories of the income statement. Additionally, it may also change the disclosure of operating activities, investing activities and financing activities within the statement of cash flows due to the change in classification of certain cash flow items. Alcon is currently evaluating the impact of adopting this standard on its Consolidated Financial Statements.
2. Significant transactions
Significant transactions in 2026
There were no significant transactions during the first half of 2026.
Significant transactions in 2025
Surgical - Acquisition of LumiThera, Inc.
On September 2, 2025, Alcon closed on a merger agreement and acquired the remaining outstanding equity of LumiThera Inc. ("LumiThera"), resulting in 100 % ownership when combined with Alcon's existing investment in LumiThera. LumiThera is a privately held, US-based company that developed and commercializes the Valeda photobiomodulation device, a multi-wavelength treatment for dry age-related macular degeneration, which supplements Alcon's Surgical portfolio. The acquisition of the equity interest was accounted for as a business combination that resulted in goodwill of $38 million after the updated preliminary purchase price allocation ("PPA") of the consideration to the fair values of acquired assets and assumed liabilities. The fair value of the assets acquired and liabilities assumed for the acquisition were based on preliminary calculations and valuations, and are subject to change as additional information is obtained during the respective measurement period up to one year from the acquisition date. Total cash paid at closing, net of cash acquired, was $124 million.
Vision Care - Acquisition of majority interest in Aurion Biotech, Inc.
On March 24, 2025, Alcon closed on agreements with certain existing shareholders of Aurion Biotech, Inc. ("Aurion") to acquire approximately 58.7 % of outstanding equity for approximately $486 million and outstanding convertible notes from the same shareholders for approximately $36 million, totaling $522 million cash paid at closing. Additionally, during 2025, Alcon acquired certain non-controlling interests in Aurion. When combined with Alcon's existing 40.3 % investment in Aurion, the transaction resulted in 99 % ownership of Aurion on an outstanding and fully diluted basis. This transaction supports Alcon's ophthalmic pharmaceutical portfolio expansion, including biopharmaceutical applications, with the potential to advance the first-ever corneal cell therapy candidate. The acquisition of majority interest was accounted for as a business combination that resulted in goodwill of $175 million. Total cash paid at closing, net of cash acquired, was $496 million. The PPA was finalized in the fourth quarter of 2025. Refer to Note 12 for additional information and final PPA.
20
Surgical - Acquisition of Cylite Pty Ltd.
On January 16, 2025, Alcon executed a stock purchase agreement and acquired approximately 91.2 % of outstanding equity from Cylite Pty Ltd. ("Cylite") shareholders, resulting in 100 % ownership when combined with Alcon's existing 8.8 % investment in Cylite. The Cylite diagnostic device complements Alcon’s existing Surgical portfolio for cataracts. The acquisition of the remaining equity interest was accounted for as a business combination that resulted in goodwill of $90 million. Total cash paid at closing, net of cash acquired, was $72 million. The PPA was finalized in the fourth quarter of 2025. Refer to Note 12 for additional information and final PPA.
3. Segmentation of key figures
The segment information disclosed in these Condensed Consolidated Interim Financial Statements reflects historical results consistent with the identifiable reportable segments of Alcon and financial information that the Chief Operating Decision Maker ("CODM") reviews to evaluate segmental performance and allocate resources among the segments. The CODM is the Executive Committee of Alcon.
The businesses of Alcon are divided operationally on a worldwide basis into two identified reportable segments, Surgical and Vision Care. Alcon's reportable segments are the same as its operating segments as Alcon does not aggregate any operating segments in arriving at its reportable segments. As indicated below, certain income and expenses are not allocated to segments.
Reportable segments are presented in a manner consistent with the internal reporting to the CODM. The reportable segments are managed separately due to their distinct needs and activities for research, development, manufacturing, distribution and commercial execution.
The Executive Committee of Alcon is responsible for allocating resources and assessing the performance of the reportable segments.
In Surgical, Alcon researches, develops, manufactures, distributes and sells ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio also includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end procedure needs of the ophthalmic surgeon.
In Vision Care, Alcon researches, develops, manufactures, distributes and sells daily disposable, reusable, and color-enhancing contact lenses, cell therapies to treat ocular diseases and a comprehensive portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma and contact lens care, as well as ocular vitamins and redness relievers.
Alcon also provides services, training, education and technical support for both the Surgical and Vision Care businesses.
The basis of preparation and the selected accounting policies mentioned in Note 1 are used in the reporting of segment results.
The Executive Committee of Alcon evaluates segmental performance and allocates resources among the segments based on net sales and segment contribution, which is the single measure of segment profitability.
Net identifiable assets are not assigned to the segments in the internal reporting to the CODM, and are not considered in evaluating the performance of the business segments by the Executive Committee of Alcon.
Segment contribution excludes amortization and impairment charges for acquired product rights or other intangibles, general and administrative expenses for corporate activities, fair value adjustments to contingent consideration liabilities, past service costs primarily for post-employment benefit plan amendments, acquisition and integration related costs, certain acquisition and divestment related items, product discontinuation costs, fair value adjustments of financial assets in the form of options to acquire a company carried at fair value through profit and loss ("FVPL"), net gains and losses on fund investments and equity securities valued at FVPL, fair value remeasurements of investments in associated companies, restructuring costs, legal provisions and settlements and other income and expense items not attributed to a specific segment.
21
Net sales and other revenues by segment
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||||
| ($ millions) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||
| Surgical | ||||||||||||||||||||
| Implantables | ||||||||||||||||||||
| Consumables | ||||||||||||||||||||
| Equipment/other | ||||||||||||||||||||
| Total Surgical net sales | ||||||||||||||||||||
| Vision Care | ||||||||||||||||||||
| Contact lenses | ||||||||||||||||||||
| Ocular health | ||||||||||||||||||||
| Total Vision Care net sales | ||||||||||||||||||||
| Total net sales | ||||||||||||||||||||
| Surgical other revenues | ||||||||||||||||||||
Vision Care other revenues | ||||||||||||||||||||
| Total other revenues | ||||||||||||||||||||
| Total net sales and other revenues | ||||||||||||||||||||
Segment contribution and reconciliation to (loss)/income before taxes
The below table summarizes segment contribution, including material items of income and expense and includes a reconciliation of segment contribution to (Loss)/income before taxes.
| Surgical | Vision Care | Not allocated to segments | Total | ||||||||||||||||||||||||||||||||
Three months ended June 30 | Three months ended June 30 | Three months ended June 30 | Three months ended June 30 | ||||||||||||||||||||||||||||||||
| ($ millions) | 2026 | 2025 | 2026 | 2025 | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||||||
| Net sales | |||||||||||||||||||||||||||||||||||
| Other revenues | |||||||||||||||||||||||||||||||||||
| Cost of net sales | ( | ( | ( | ( | ( | ( | ( | ( | |||||||||||||||||||||||||||
| Cost of other revenues | ( | ( | ( | ( | ( | ||||||||||||||||||||||||||||||
| Selling, general & administration | ( | ( | ( | ( | ( | ( | ( | ( | |||||||||||||||||||||||||||
| Research & development | ( | ( | ( | ( | ( | ( | ( | ( | |||||||||||||||||||||||||||
| Other income | |||||||||||||||||||||||||||||||||||
| Other expense | ( | ( | ( | ( | |||||||||||||||||||||||||||||||
| Segment contribution and Operating income | ( | ( | |||||||||||||||||||||||||||||||||
| Interest expense | ( | ( | ( | ( | |||||||||||||||||||||||||||||||
| Other financial income & expense | |||||||||||||||||||||||||||||||||||
| Share of loss from associated companies | ( | ( | ( | ( | |||||||||||||||||||||||||||||||
| (Loss)/income before taxes | ( | ||||||||||||||||||||||||||||||||||
22
| Surgical | Vision Care | Not allocated to segments | Total | ||||||||||||||||||||||||||||||||
Six months ended June 30 | Six months ended June 30 | Six months ended June 30 | Six months ended June 30 | ||||||||||||||||||||||||||||||||
| ($ millions) | 2026 | 2025 | 2026 | 2025 | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||||||
| Net sales | |||||||||||||||||||||||||||||||||||
| Other revenues | |||||||||||||||||||||||||||||||||||
| Cost of net sales | ( | ( | ( | ( | ( | ( | ( | ( | |||||||||||||||||||||||||||
| Cost of other revenues | ( | ( | ( | ( | ( | ( | |||||||||||||||||||||||||||||
| Selling, general & administration | ( | ( | ( | ( | ( | ( | ( | ( | |||||||||||||||||||||||||||
| Research & development | ( | ( | ( | ( | ( | ( | ( | ( | |||||||||||||||||||||||||||
| Other income | |||||||||||||||||||||||||||||||||||
| Other expense | ( | ( | ( | ( | |||||||||||||||||||||||||||||||
| Segment contribution and Operating income | ( | ( | |||||||||||||||||||||||||||||||||
| Interest expense | ( | ( | ( | ( | |||||||||||||||||||||||||||||||
| Other financial income & expense | |||||||||||||||||||||||||||||||||||
| Share of loss from associated companies | ( | ( | ( | ( | |||||||||||||||||||||||||||||||
| Income before taxes | |||||||||||||||||||||||||||||||||||
Net sales by region(1)
| Three months ended June 30 | Six months ended June 30 | ||||||||||||||||||||||||||||
| ($ millions unless indicated otherwise) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||||
| United States | % | % | % | % | |||||||||||||||||||||||||
| International | % | % | % | % | |||||||||||||||||||||||||
| Net sales | % | % | % | % | |||||||||||||||||||||||||
(1) Net sales by location of third-party customer.
4. Dividends, earnings per share and share repurchase program
Dividends
On February 24, 2026, the Company's Board of Directors (the "Board") proposed a dividend of CHF 0.28 per share, which was subsequently approved by the shareholders at the Annual General Meeting on April 30, 2026 and paid in May 2026 for an amount of $174 million.
On February 25, 2025, the Board proposed a dividend of CHF 0.28 per share, which was subsequently approved by the shareholders at the Annual General Meeting on May 6, 2025 and paid in May 2025 for an amount of $166 million.
Earnings per share
As of June 30, 2026, there were 483.4 million outstanding common shares after the delivery of 1.3 million net shares vesting under the equity incentive programs, partially offset by repurchases of 5.3 million common shares during the six months ended June 30, 2026.
Basic earnings per share is computed by dividing net income attributable to shareholders of Alcon Inc. for the period by the weighted average number of common shares outstanding during the period. For the three and six months ended June 30, 2026, the weighted average number of shares outstanding was 486.7 million and 486.9 million, respectively. For both the three and six months ended June 30, 2025, the weighted average number of shares outstanding was 495.2
23
The only potentially dilutive securities are the outstanding unvested equity-based awards, as described in Note 9. Except when the effect would be anti-dilutive, the calculation of diluted earnings per common share includes the weighted average net impact of unvested equity-based awards. For the three and six months ended June 30, 2026, the weighted average diluted number of shares outstanding was 488.7 million and 489.4 million, respectively, which includes the potential conversion of 2.0 million and 2.5 million unvested equity-based awards, respectively. For both the three and six months ended June 30, 2025, the weighted average diluted number of shares outstanding was 497.9 2.7
Share repurchase programs
Alcon made share repurchases in January 2026 under the initial share repurchase program, (the "2025 Repurchase Program"), which was announced in 2025 and completed on January 20, 2026 with 9.3 million shares repurchased for a total of $750 million during the duration of the program.
On May 5, 2026, the Board authorized the repurchase of up to $1.5 billion of the Company’s common shares, par value of CHF 0.04 per share, on a second trading line with the SIX Swiss Exchange, (the "2026 Repurchase Program"). The shares to be acquired under this share buyback program will be cancelled as a return of capital to shareholders.
Alcon expects to fund the 2026 Repurchase Program through cash generated from operations. The 2026 Repurchase Program is subject to customary safe harbor conditions and authorization of the Swiss Takeover Board. The timing and total amount of share repurchases and cancellations will depend upon a variety of factors. The 2026 Repurchase Program is expected to be completed over a three-year period, but may be suspended or discontinued at any time. Alcon commenced share repurchases under the 2026 Repurchase Program on May 7, 2026.
During the six months ended June 30, 2026, 5.3 million shares were repurchased for a total consideration of $364 million under both the 2025 Repurchase Program and the 2026 Repurchase Program. Total cash payments of $353 million for the acquisition of treasury shares for the six months ended June 30, 2026 were recorded to Payments for acquisition of treasury shares within the financing section of the Condensed Consolidated Statement of Cash Flows. Liabilities of $17 million were recorded to Provisions & other current liabilities for share repurchases which were initiated but not settled as of June 30, 2026. No shares have been cancelled as of June 30, 2026.
5. Intangible assets other than goodwill
Intangible asset impairment charges
Impairment charges during the three months ended June 30, 2026 amounted to $505 million, recognized in Research & development in the Condensed Consolidated Income Statement due to the full impairment of the IOL programs acquired from PowerVision, Inc. in March 2019 ("PowerVision programs") cash generating unit ("CGU") in the Surgical reportable segment due to discontinuation of the PowerVision programs following the analysis of the latest clinical study data. The discontinuation of the PowerVision programs also resulted in a fair value adjustment of $103 million to contingent consideration liabilities in Provisions & other non-current liabilities and recognized in Research & development in the Condensed Consolidated Income Statement. In addition, there was a $115 million reversal of Deferred tax liabilities and recognized in Taxes in the Condensed Consolidated Income Statement. Impairment charges during the six months ended June 30, 2026 amounted to $543 million, including $505 million described above in the second quarter and a remaining amount of $38 million recognized in Cost of net sales in the Condensed Consolidated Income Statement in the first quarter due to the partial impairment of a currently marketed product CGU in the Vision Care reportable segment due to challenges gaining prescription share. The CGU was reduced to its recoverable amount of $9 million determined based on the value in use method with a discount rate of 8.25 % at the time of impairment.
Impairment charges during the three months and six months ended June 30, 2025 amounted to $43
24
6. Non-current and current financial debts
The below table summarizes non-current and current Financial debts outstanding as of June 30, 2026 and December 31, 2025.
| ($ millions) | June 30, 2026 | December 31, 2025 | ||||||||||||
| Non-current financial debts | ||||||||||||||
Local facilities (Japan), floating rate debt due 2028 | ||||||||||||||
Revolving facility, floating rate due 2030 | ||||||||||||||
| Total non-current financial debts | ||||||||||||||
| Current financial debts | ||||||||||||||
| Local facilities, floating rate: | ||||||||||||||
Japan | ||||||||||||||
| All others | ||||||||||||||
| Other short-term financial debts, floating rate | ||||||||||||||
| Derivatives | ||||||||||||||
| Total current financial debts | ||||||||||||||
| Total financial debts | ||||||||||||||
Interest expense recognized for Financial debts was $43 million and $85 million for the three and six months ended June 30, 2026, respectively, and $43 million and $84 million for the three and six months ended June 30, 2025, respectively.
Revolving credit facility
25
7. Financial instruments
Fair value by hierarchy
As required by IFRS, financial assets and liabilities recorded at fair value in the Condensed Consolidated Interim Financial Statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on an increasing amount of judgment associated with the inputs to derive fair value for these financial assets and liabilities, which are as follows:
Financial assets and liabilities carried at Level 1 fair value hierarchy are listed in active markets.
Financial assets and liabilities carried at Level 2 fair value hierarchy are valued using corroborated market data.
Level 1 financial assets include money market funds, equity securities in public companies and deferred compensation assets. There were no financial liabilities carried at Level 1 fair value, and Level 2 financial assets and liabilities include derivative financial instruments.
Investments in money market funds and equity securities in public companies are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Investments in money market funds are classified as Cash & cash equivalents within the Condensed Consolidated Balance Sheet.
Deferred compensation investments for certain employee benefit plans are held in a rabbi trust and dedicated to pay the benefits under the associated plans but are not considered plan assets as the assets remain available to creditors of Alcon in certain events, including bankruptcy. Rabbi trust assets primarily consist of investments in mutual funds. These assets are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.
Level 3 inputs are unobservable for the financial asset or liability. Fair value measurements classified as Level 3 are performed primarily using the income approach or market approach. The financial assets and liabilities generally included in the Level 3 fair value hierarchy are equity securities and convertible notes receivable of private companies measured at fair value through other comprehensive income ("FVOCI"), fund investments, options to acquire private companies and contingent consideration liabilities measured at FVPL.
26
The below table summarizes financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2026 and December 31, 2025.
June 30, 2026 | December 31, 2025 | ||||||||||||||||||||||||||||
| ($ millions) | Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||
| Non-current financial assets | |||||||||||||||||||||||||||||
Long-term financial investments measured at FVOCI | |||||||||||||||||||||||||||||
| Long-term financial investments measured at FVPL | |||||||||||||||||||||||||||||
Deferred compensation assets(1) | |||||||||||||||||||||||||||||
| Non-current financial assets at fair value | |||||||||||||||||||||||||||||
| Current financial assets | |||||||||||||||||||||||||||||
| Money market funds | |||||||||||||||||||||||||||||
Current portion of long-term financial investments measured at FVPL(2) | |||||||||||||||||||||||||||||
Derivative financial instruments(2) | |||||||||||||||||||||||||||||
| Current financial assets at fair value | |||||||||||||||||||||||||||||
| Financial assets at fair value | |||||||||||||||||||||||||||||
| Non-current financial liabilities | |||||||||||||||||||||||||||||
| Non-current contingent consideration liabilities | ( | ( | ( | ( | |||||||||||||||||||||||||
| Non-current financial liabilities at fair value | ( | ( | ( | ( | |||||||||||||||||||||||||
| Current financial liabilities | |||||||||||||||||||||||||||||
| Current contingent consideration liabilities | ( | ( | ( | ( | |||||||||||||||||||||||||
Derivative financial instruments | ( | ( | ( | ( | |||||||||||||||||||||||||
| Current financial liabilities at fair value | ( | ( | ( | ( | ( | ( | |||||||||||||||||||||||
| Financial liabilities at fair value | ( | ( | ( | ( | ( | ( | |||||||||||||||||||||||
(1) Recorded in Other non-current assets.
(2) Recorded in Other current assets.
There were no transfers of financial assets or liabilities between levels in the fair value hierarchy during the six months ended June 30, 2026.
The carrying amount is a reasonable approximation of fair value for all other financial instruments as of June 30, 2026 and December 31, 2025, with the exception of the Series 2026, 2028, 2029, 2030, 2032, 2049 and 2052 Notes ("Notes"). The Notes are recorded in Non-current financial debts, with the exception of the Series 2026 Notes, which are recorded in Current financial debts. As of June 30, 2026, the Notes had a fair value of $4,384 million and a carrying value of $4,595 million. As of December 31, 2025, the Notes had a fair value of $4,466 million and a carrying value of $4,608 million. The fair value of the Notes was determined using Level 2 inputs. The Notes were valued using the quoted market price for such Notes, which have low trading volumes.
27
Level 3 financial instruments measured at fair value on a recurring basis
Financial assets
| Long-term financial investments measured at FVOCI | Financial investments measured at FVPL | |||||||||||||||||||
| ($ millions) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||
| Balance as of January 1 | ||||||||||||||||||||
| Additions | ||||||||||||||||||||
| Net losses recognized in Consolidated Statement of Comprehensive (Loss)/Income | ( | ( | ||||||||||||||||||
| Amortization | ( | ( | ||||||||||||||||||
| Settlements | ( | |||||||||||||||||||
| Balance as of June 30 | ||||||||||||||||||||
Financial liabilities
| Contingent consideration liabilities | ||||||||
| ($ millions) | 2026 | 2025 | ||||||
| Balance as of January 1 | ( | ( | ||||||
| Additions | ( | |||||||
| Accretion for passage of time | ( | ( | ||||||
| Adjustments for changes in assumptions | ||||||||
| Balance as of June 30 | ( | ( | ||||||
Changes in contingent consideration liabilities in the current year period include fair value adjustments for changes in assumptions of $103 million due to revised expectations for achievement of development and commercial milestones related to the discontinuation of the PowerVision programs. Refer to Note 5 for additional information.
Additions to contingent consideration liabilities in the prior year period relate to the Cylite acquisition. Refer to Note 12 for additional information.
As of June 30, 2026, the probability of success for various development and commercial milestones ranges from 0 % to 95 % and the maximum remaining potential payments related to contingent consideration from business combinations is $1.1 billion, plus other amounts calculated as a percentage of commercial sales in cases where there is not a specified maximum contractual payment amount. The estimation of probability typically depends on factors such as technical milestones or market performance and is adjusted for the probability of payment. If material, probable payments are appropriately discounted to reflect the impact of time.
Contingent consideration liabilities are reported in Provisions & other non-current liabilities and Provisions & other current liabilities based on the projected timing of settlement, which is estimated to range from late 2026 through 2039 for contingent consideration obligations as of June 30, 2026.
28
Time deposits
During 2026, Alcon purchased time deposits of $100 million with a six-month term maturing on October 29, 2026. The time deposits are measured at amortized cost and had a carrying value of $101 million as of June 30, 2026.
Long-term note receivable and other financial assets measured at amortized cost
As described in Note 17 to the Consolidated Financial Statements in the Form 20-F, on May 22, 2023, Alcon entered into financing arrangements with a long-term supplier, Lifecore Biomedical, Inc. and certain of its affiliates (collectively, “Lifecore”) resulting in financial assets which Alcon concluded were originated credit-impaired. The maximum exposure to credit risk is reflected in the carrying value of the assets, which amounted to $200 million as of June 30, 2026, including a non-current portion of $199 million in Financial assets and a current portion of $1 million in Other current assets. As of June 30, 2026, in accordance with the terms of the Pledge and Security agreement (“security agreement”), the credit risk exposure is fully mitigated by the collateral, with an estimated amount of approximately $420 million. There have been no significant changes in the quality of the collateral, the terms of the signed security agreement or the credit monitoring procedures described in Note 17 to the Consolidated Financial Statements in the Form 20-F. In addition, as of June 30, 2026, Alcon assessed there was no lifetime expected credit loss due to the value of the collateral under the security agreement.
Derivatives
The below table summarizes the net value of unsettled positions for currency derivatives contracts including swaps, forwards and options as of June 30, 2026 and December 31, 2025.
| ($ millions) | June 30, 2026 | December 31, 2025 | ||||||
Unrealized gains in Other current assets | ||||||||
Unrealized losses in Current financial debts | ( | ( | ||||||
Net value of unsettled positions for derivatives contracts | ( | |||||||
There are master agreements with several banking counterparties for derivative financial instruments; however, there were no derivative financial instruments meeting the offsetting criteria under IFRS as of June 30, 2026 or December 31, 2025.
Nature and extent of risks arising from financial instruments
Note 17 to the Consolidated Financial Statements in the Form 20-F contains a summary of the nature and extent of risks arising from financial instruments. There have been no significant updates to our assessment of the nature and extent of risks arising from financial instruments or corresponding risk management policies during the period.
29
8. Condensed Consolidated Statement of Cash Flows - additional details
The below tables provide additional detail supporting select line items in the Condensed Consolidated Statement of Cash Flows.
8.1 Depreciation, amortization, impairments and fair value adjustments
| Six months ended June 30 | ||||||||||||||
| ($ millions) | 2026 | 2025 | ||||||||||||
| Property, plant & equipment | ||||||||||||||
| Right-of-use assets | ||||||||||||||
| Intangible assets | ||||||||||||||
Other non-current assets(1) | ( | |||||||||||||
| Total | ||||||||||||||
(1) For the six months ended June 30, 2025, Other non-current assets includes gains on fair value remeasurements of investments in associated companies. Refer to Note 12 for additional information.
8.2 Change in net current assets and other operating cash flow items
| Six months ended June 30 | ||||||||||||||
| ($ millions) | 2026 | 2025 | ||||||||||||
| (Increase) in inventories | ( | ( | ||||||||||||
| (Increase) in trade receivables | ( | ( | ||||||||||||
| Increase in trade payables | ||||||||||||||
| Net change in other operating assets | ( | ( | ||||||||||||
| Net change in other operating liabilities | ( | ( | ||||||||||||
| Total | ( | ( | ||||||||||||
9. Equity-based compensation
As described in Note 23 to the Consolidated Financial Statements in the Form 20-F, Alcon has various equity incentive plans, under which Alcon may grant awards in the form of restricted stock units ("RSUs"), performance-based restricted stock units ("PSUs"), restricted stock awards ("RSAs"), or any other form of award at the discretion of the Board. Certain associates in select countries may also participate in share ownership savings plans.
The below table summarizes unvested share movements for all Alcon equity-based incentive plans for the six months ended June 30, 2026 and 2025.
| Six months ended June 30 | ||||||||||||||
| (shares in millions) | 2026 | 2025 | ||||||||||||
| Unvested at January 1 | ||||||||||||||
| Granted | ||||||||||||||
| Vested | ( | ( | ||||||||||||
| Forfeited | ( | ( | ||||||||||||
| Unvested at June 30 | ||||||||||||||
30
10. Legal proceedings update
A number of Alcon companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability, sales and marketing practices, commercial disputes, mergers and acquisitions, employment, wrongful discharge, antitrust, securities, health and safety, environmental, tax, international trade, privacy, intellectual property, including under the Hatch-Waxman Act, and anti-bribery matters such as those under the Foreign Corrupt Practices Act of 1977, as amended.
As a result, Alcon may become subject to substantial liabilities that may not be covered by insurance and could affect Alcon's business, financial position and reputation. While Alcon does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Alcon may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. Note 18 to the Consolidated Financial Statements in the Form 20-F contains a summary of significant legal proceedings to which Alcon or any of its subsidiaries was a party as of the date of the Form 20-F. In July 2024, Alcon received a Civil Investigative Demand from the U.S. Department of Justice (“DoJ”) in connection with a civil investigation under the False Claims Act relating to discounts on surgical equipment servicing contracts. On May 20, 2026, DoJ informed Alcon that it declined to intervene in a recently unsealed qui tam action entitled United States ex rel. Ball vs. Alcon Inc., et al., No. 2:23-cv-03414-NIQA (E.D. Pa.), thereby concluding the investigation underlying the Civil Investigative Demand.
As of August 10, 2026, there have been no other significant developments in the proceedings described in the Form 20-F nor any new significant proceedings commenced since the date of the Form 20-F.
Alcon believes that its total provisions for litigation and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, additional liabilities and costs may be incurred beyond the amounts provided.
11. Restructuring provisions
On February 24, 2026, Alcon announced certain efficiency measures supported by operational improvements and infrastructure investments. The additions to restructuring provisions in the six months ended June 30, 2026 were for these efficiency measures and were related to accrued severance for the associates whose positions were eliminated. The below table shows the movement of restructuring provisions, which is included in Provisions and other current liabilities in the Condensed Consolidated Balance Sheet.
| ($ millions) | 2026 | 2025 | |||||||||
| January 1 | |||||||||||
| Additions | |||||||||||
| Cash payments | ( | ||||||||||
| Balance as of June 30 | |||||||||||
31
12. Acquisitions
Acquisitions of businesses
During the first six months of 2026, there were no acquisitions of businesses. During the first six months of 2025, acquisitions of businesses included Aurion Biotech, Inc. and Cylite Pty Ltd., described below.
Vision Care - Acquisition of majority interest in Aurion Biotech, Inc.
On March 24, 2025, Alcon closed on agreements with certain existing shareholders of Aurion to acquire approximately 58.7 % of outstanding equity for approximately $486 million and outstanding convertible notes from the same shareholders for approximately $36 million, totaling $522 million cash paid at closing. Additionally, during 2025, Alcon acquired certain non-controlling interests in Aurion. When combined with Alcon's existing 40.3 % investment in Aurion, the transaction resulted in 99 % ownership of Aurion on an outstanding and fully diluted basis. This transaction supports Alcon's ophthalmic pharmaceutical portfolio expansion, including biopharmaceutical applications, with the potential to advance the first-ever corneal cell therapy candidate. The acquisition of majority interest was accounted for as a business combination that resulted in goodwill of $175 million. Total cash paid at closing, net of cash acquired, was $496 million. The transaction also resulted in non-controlling interests.
The acquisition date fair value of the equity interest previously held by Alcon was $334 million, resulting in a remeasurement fair value gain of $136 million in the first quarter of 2025. The fair value gain has been included in Other income in the 2025 Condensed Consolidated Income Statement.
The below table summarizes the final PPA for the Aurion business combination which was finalized in the fourth quarter of 2025.
| ($ millions) | Final PPA | ||||||||||
| Property, plant and equipment | |||||||||||
| Right-of-use assets | |||||||||||
| Current marketed products | |||||||||||
| Acquired IPR&D | |||||||||||
| Deferred tax assets | |||||||||||
| Other current assets | |||||||||||
| Cash and cash equivalents | |||||||||||
| Non-current lease liabilities | ( | ||||||||||
| Non-current financial debts | ( | ||||||||||
| Deferred tax liabilities | ( | ||||||||||
| Current financial debts | ( | ||||||||||
| Current lease liabilities | ( | ||||||||||
| Current income tax liabilities | ( | ||||||||||
| Trade payables | ( | ||||||||||
| Provisions and other current liabilities | ( | ||||||||||
| Net identifiable assets acquired | |||||||||||
| Goodwill | |||||||||||
| Non-controlling interests | ( | ||||||||||
| Net assets acquired as a result of business combination | |||||||||||
| Cash paid at closing | |||||||||||
| Previously-held investment in associated company | |||||||||||
| Total acquisition date fair value of consideration | |||||||||||
Direct acquisition costs of $2 million were recognized in Other expense in the 2025 Condensed Consolidated Income Statement and were reported in operating cash flows in the 2025 Condensed Consolidated Statement of Cash Flows.
32
Pro forma financial information is not presented for the Aurion business acquisition as it is not material to the 2025 Condensed Consolidated Financial Statements.
For the period from the date of the Aurion acquisition, March 24, 2025, through June 30, 2025, the acquired business reduced Alcon's Net income by $17 million.
Surgical - Acquisition of Cylite Pty Ltd.
On January 16, 2025, Alcon executed a stock purchase agreement and acquired approximately 91.2 % of outstanding equity from Cylite shareholders, resulting in 100 % ownership when combined with Alcon's existing 8.8 % investment in Cylite. The Cylite diagnostic device complements Alcon’s existing Surgical portfolio for cataracts. The acquisition of the remaining equity interest was accounted for as a business combination that resulted in goodwill of $90 million. Total cash paid at closing, net of cash acquired, was $72 million.
The development milestone contingent consideration is related to a potential payment of up to $10 million upon achievement of the first commercial sale of a defined product within the United States. The contingent consideration recognized during the first quarter of 2025 represents its fair value (Level 3) at the acquisition date.
The acquisition date fair value of the equity interest previously held by Alcon was $14 million, resulting in a remeasurement fair value gain of $6 million in the first quarter of 2025. The fair value gain has been included in Other income in the 2025 Condensed Consolidated Income Statement.
The below table summarizes the final PPA for the Cylite business combination which was finalized in the fourth quarter of 2025.
| ($ millions) | Final PPA | |||||||||||||||||||
| Property, plant and equipment | ||||||||||||||||||||
| Right-of-use assets | ||||||||||||||||||||
| Current marketed products | ||||||||||||||||||||
| Acquired IPR&D | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Deferred tax liabilities | ( | |||||||||||||||||||
| Lease liabilities | ( | |||||||||||||||||||
| Trade payables | ( | |||||||||||||||||||
| Provisions and other current liabilities | ( | |||||||||||||||||||
| Net identifiable assets acquired | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Net assets acquired as a result of business combination | ||||||||||||||||||||
| Cash paid at closing | ||||||||||||||||||||
| Cash expected to be paid after closing | ||||||||||||||||||||
| Previously-held FVOCI financial investment | ||||||||||||||||||||
| Previously-held commercialization rights in intangible assets | ||||||||||||||||||||
| Contingent consideration | ||||||||||||||||||||
| Previously-held investment in associated company | ||||||||||||||||||||
| Total acquisition date fair value of consideration | ||||||||||||||||||||
Goodwill is attributable primarily to buyer-specific synergies, including benefits to intraocular lens sales, development collaboration arrangement and associated development timeline reduction and assembled workforce. The goodwill is not deductible for tax purposes.
Direct acquisition costs of $1 million were recognized in Other expense in the 2025 Condensed Consolidated Income Statement and were reported in operating cash flows in the 2025 Condensed Consolidated Statement of Cash Flows.
Pro forma financial information is not presented for the Cylite business acquisition as it is not material to the 2025 Condensed Consolidated Financial Statements.
33
For the period from the date of the Cylite acquisition, January 16, 2025, through June 30, 2025, the acquired business reduced Alcon's Net income by $8 million.
Termination of proposed acquisition of LENSAR, Inc.
On March 23, 2025, Alcon entered into a definitive agreement to acquire all outstanding shares of LENSAR, Inc. ("LENSAR"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, with a total consideration of up to approximately $430 million. On March 16, 2026, Alcon entered into an agreement with LENSAR to terminate the previously announced merger agreement.
13. Related parties transactions
Associated companies
As of June 30, 2026, Alcon holds voting interests of approximately 21.4 % in an associated company. Investments in associated companies are accounted for using the equity method as Alcon is considered to have significant influence.
The below table summarizes activity related to investments in associated companies for the six months ended June 30, 2026 and 2025.
| Investments in associated companies | ||||||||
| ($ millions) | 2026 | 2025 | ||||||
| Balance as of January 1 | ||||||||
| Purchases | ||||||||
| Share of loss from associated companies recognized in Consolidated Income Statement | ( | ( | ||||||
Gains on fair value remeasurements recognized in Consolidated Income Statement(1) | ||||||||
Recognition of business combinations(1) | ( | |||||||
| Balance as of June 30 | ||||||||
(1) Refer to Note 12 for additional information.
On May 11, 2026, Alcon entered into a financing arrangement with a supplier for one of its majority-owned subsidiaries under which Alcon provided funding of $25 million in exchange for a note receivable maturing on May 11, 2033. Although Alcon is considered to have significant influence under the terms of the arrangement, Alcon does not hold any outstanding or potential equity interest with the supplier. The note receivable is accounted for as a financial asset measured at amortized cost.
As of June 30, 2026, the carrying amount of the note receivable was $25 million and was recorded in Financial assets on the Condensed Consolidated Balance Sheet. For the six months ended June 30, 2026, purchases from the supplier amounted to $0.2 million for the supply of materials.
14. Subsequent events
These unaudited Condensed Consolidated Interim Financial Statements were authorized for issue by the Audit & Risk Committee on August 10, 2026.
34
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This document contains, and our officers and representatives may from time to time make, certain “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “target,” “assume,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our 2026 outlook, liquidity, revenue, revenue growth, gross margin, operating margin, core operating margin, core operating margin growth, effective tax rate, foreign currency exchange movements, tariff impact, non-operating expenses, earnings per share, earnings per share growth, operating cash flow, free cash flow, our plans and decisions relating to various capital expenditures, capital allocation priorities and other discretionary items such as our market growth assumptions, our social impact and sustainability plans, targets, goals and expectations, and generally, our expectations concerning our future performance.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict such as: cybersecurity breaches and technology failures that could disrupt operations; our ability to effectively manage the risks associated with transformational information technology changes such as the ethical use of artificial intelligence and disruptive technologies and the migration to cloud-based platforms; compliance with data privacy, identity protection and information security laws, particularly with the increased use of artificial intelligence; the impact of a disruption in our global supply chain, including the effect of tariffs, or important facilities, particularly when we single-source or rely on limited sources of supply; our reliance on outsourcing key business functions; the increasingly challenging economic, political and legal environment in China; global and regional economic, financial, monetary, legal, tax, political and social change; our ability to comply with anti-corruption, anti-bribery, export control, trade sanction, or similar laws; our ability to attract and retain qualified personnel; our ability to manage the risks associated with operating as a third party contract manufacturer; our success in completing strategic acquisitions, including equity investments in early-stage companies, on favorable terms or at all, and in integrating acquired businesses; the success of our research and development efforts, including our ability to innovate to compete effectively; our ability to manage the rapid evolution and adoption of artificial intelligence; terrorism, war and similar events; our ability to forecast sales demand and manage our inventory levels and the changing buying patterns of our customers; pricing pressure from changes in third party payor coverage and reimbursement methodologies; our ability to comply with all laws to which we may be subject; the ability to obtain regulatory clearance and approval of our products as well as compliance with any post-approval obligations, including quality control of our manufacturing; the effect of product recalls or voluntary market withdrawals; our ability to manage social impact and sustainability matters; our ability to properly educate and train healthcare providers on our products; our ability to protect our intellectual property; the accuracy of our accounting estimates and assumptions, including pension and other post-employment benefit plan obligations and the carrying value of intangible assets, and the adequacy of our financial reporting, accounting practices and internal controls; our ability to service our debt obligations; the need for additional financing through the issuance of debt or equity; the effects of litigation, including product liability lawsuits and governmental investigations; legislative, tax and regulatory reform; the impact of being listed on two stock exchanges; the ability to declare and pay dividends; the different rights afforded to our shareholders as a Swiss corporation compared to a US corporation; the effect of maintaining or losing our foreign private issuer status under US securities laws; and the ability to enforce US judgments against Swiss corporations.
Additional factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this document speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise. We also undertake no obligation to update the 2026 outlook as circumstances evolve.
INTELLECTUAL PROPERTY
This report may contain reference to our proprietary intellectual property. All product names appearing in italics are trademarks owned by or licensed to Alcon Inc. Product names identified by a "®" or a "™" are trademarks that are not owned by or licensed to Alcon or its subsidiaries and are the property of their respective owners.
35
ABOUT ALCON
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
Connect with us on 
36